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INTRODUCTION 
  Bloodstream infections are one of the serious and life-threatening clinical 
conditions leading to deleterious consequences with mortality rate ranging 
from 20-40 % 1, 2. Hence, needs immediate attention and treatment. 
 Advances in blood culture techniques have resulted in efficient and reliable 
methodologies for the detection of causative pathogens. 
 Bloodstream infections are classified traditionally as nosocomial and 
community acquired bloodstream infections 3, 4. 
 Community acquired bloodstream infections refers to the infections detected 
within 48 hours of hospitalization, showing positive blood culture and 
develops spontaneously without an association with any prior medical 
interventions 5. 
 Community acquired bloodstream infections are becoming a major health 
problem in the upcoming years due to the emergence of antimicrobial resistant 
organisms in community settings as causative agents like,  ESBL producing 
Enterobacteriaceae, Methicillin resistant Staphylococcus aureus etc...6 
 Antimicrobial resistant strains once confined to hospital settings are now a 
potential threat in the community too. 
 Rapid detection of antimicrobial resistant strain is highly essential, as they are 
associated with increased mortality and morbidity and due to their high 
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propensity to spread and able to cause a serious threat to public health 
concern. 
 Phenotypic characterization of microorganisms helps in identification of 
causative agents of infectious diseases. 
 Molecular characterization of resistant pathogens aids in tracking the spread 
of antimicrobial resistance in community and hospital settings. 
 Sepsis, since 1991, defined as the combination of infection with 2 or more 
features of systemic inflammatory response syndrome(SIRS): 7 
1) Body temperature >38⁰c or <36⁰c 
2) Heart rate >90 beats/min 
3) Respiratory rate >20 breaths/min 
4) White blood cell count >12x10⁹/L or <4x10⁹/L                                                               
 Additional criteria for sepsis – altered mental status, edema, hyperglycemia in 
the absence of diabetes and elevated biomarkers of sepsis such as C - reactive 
protein, interleukins etc.., 8 
 Since 2014, sepsis is defined as a life threatening organ dysfunction caused by 
a dysregulated host response to infection in addition to above parameters.9 
 
 C-reactive protein is an acute phase reactant protein whose synthesis in liver is 
upregulated by Interleukin-6.It is a well established biomarker of infection and 
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inflammation. Commonly used to screen for early onset sepsis, as its 
sensitivity is found to be very high in this setting 10, 11. 
 Interleukin-6 is an immune protein in the hematopoeitins family. It is a 
monomer of 184 amino acids produced by T-cells, macrophages and 
endothelial cells found on a single gene located at 7p21.It is released in 
response to infections, burns, trauma, neoplasia etc.. 
 Interleukin-6 meets one of the desired attributes of an ideal biomarker of 
sepsis because it is capable of identifying  those patients with sepsis, who are 
at increased risk of developing severe sepsis and who therefore needs 
supportive therapy.12 
 Hence, inflammatory markers have a diagnostic and prognostic value in    
detection of sepsis. 
  
Aims &objectives 
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AIMS AND OBJECTIVES 
 
1. To identify the clinical profile of patients with community acquired blood 
stream infections. 
2. To detect the pathogens causing community acquired blood stream infections 
and their antimicrobial susceptibility pattern. 
3. Correlation of inflammatory markers with blood culture positivity. 
4. To assess the prognosis, severity and outcome of disease with the 
inflammatory markers. 
5. To perform the molecular characterization of resistant pathogens. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 Sepsis is a devastating, life threatening medical emergency, which needs 
immediate attention and treatment. 
 
HISTORY OF SEPSIS- 
 The word “sepsis” originated from an ancient Greek word [σηψις] which 
means “decomposition of animal, vegetable or organic matter in the presence of 
bacteria”.13 
 
 The word “sepsis” got its origin during Hippocrates period (ca.460-370BC) 
who was a great physician and philosopher, known in medical field as the “Father 
of modern medicine”14 
 
 Ignaz Semmelweis, (1818-1865), further developed his modern views on 
sepsis. He was an obstetrician and has done major work on “Etiology, terminus 
and prophylaxis of puerperal fever”. Also detected childbed fever was caused by 
“decomposed animal matter which entered the bloodstream” and he also 
succeeded in reducing the mortality rate by introducing a new system, hand 
washing with a chlorinated lime solution before every gynecological examination. 
But his works were not accepted and were not well appreciated and practiced at 
that period of time. 
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 Louis Pasteur, a French chemist (1822-1895) discovered the fact that tiny 
single celled organisms which he called bacteria or microbes caused putrefaction, 
in other words “sepsis”. 
 
 Joseph Lister (1827-1912), a surgeon found that, in his hospital about 50% 
of patients following amputation procedure died of sepsis. Then he correlated 
Semmelweis findings, Pasteur’s views and deaths which occurred in his hospital, 
and as a result he introduced his “antiseptic method” successfully by examining 
the effects of skin and instrument disinfection with carbolic acid. 
 
 It was Hugo Schottmuller (1867-1936), student of H. Lennhartz, a German 
physician in 1914 gave a modern definition for sepsis as follows: 
 
 “Sepsis is present if there is a focus from which pathogenic bacteria invade 
the bloodstream either constantly or periodically, so as to cause the subjective and 
objective symptoms”. 
 
 From above definition, it was understood for the first time, that source of 
infection came into focus as a cause of sepsis. 
 
 During the pre-antibiotic time, mortality rates from sepsis were very high. 
Only after introduction of effective antibiotics after worldwarII, mortality rates 
due to sepsis reduced. With progress in technology, Intensive medical care units 
started to develop and sepsis patients became the main fractions who were dealt 
with, under these units. 
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 In 1989, US American ICU specialist, Roger C. Bone (1941-1997), 
introduced the concept of sepsis syndrome and gave a new definition for sepsis, 
which is still valid until today. “Sepsis is defined as a systemic response to a 
suspected or documented infection with at least one organ dysfunction”.15, 16 
 
Definition of Sepsis: 
The old and new definitions and concepts of sepsis is as follows-  
 
Sepsis –definition1 
 1991 Consensus Conference convened by the Society of Critical Care 
Medicine and the American College of chest physician, defined17  
 
 Sepsis as the systemic response to infection and as a result of infection 
manifests by two or more of SIRS criteria.  
 
 Severe sepsis is sepsis associated with organ dysfunction, hypo perfusion 
or hypotension. 
 
 Septic Shock is sepsis with hypotension despite adequate fluid 
resuscitation along with the presence of perfusion abnormalities. 
 
SIRS criteria 
(a) Temperature > 38℃  or <36℃ 
(b) Heart rate >90 beats per minute 
(c) Respiratory rate >20 breaths per minute or paco₂ <32mmHg 
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(d) White Blood Cell count >12,000/cumm, <4,000/cumm, or 10% immature 
(band) forms. 
 
Sepsis- definition2 
 2001 Consensus Conference sponsored by the Society of Critical Care 
Medicine, the European society of Intensive Care Medicine, the American college 
of clinical pharmacy, the American thoracic society and the Surgical Infection 
Society gave a detailed diagnostic criteria for sepsis as follows-17 
 
a) Infection – suspected or documented. 
b) General parameters- 
(1) Fever >38℃ or <36℃ 
(2) Heart rate >90 beats/minute 
(3) Respiratory rate >30 breaths per minute 
(4) Altered Mental Status 
(5) Edema 
(6) Hyperglycemia in the absence of diabetes. 
c) Inflammatory parameters- 
(1) white blood cell count >12,000/ L or <4,000/ L 
(2) Plasma C – reactive protein >2SD above the normal value 
(3) Plasma procalcitonin >2SD above the normal value 
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d) Hemodynamic parameters- 
(1) Hypotension (systolic blood pressure 90mmHg) 
(2) Mixed venous oxygen saturation >70% 
 
e) Organ dysfunction parameters- 
(1) Acute oliguria (urine output <0.5ml/kg/hr for at least 2hrs and increase in 
Sr.creatinine > 0.5mg/dl) 
(2) Arterial Hypoxemia (pao₂/Fio₂<300) 
(3) Coagulation abnormalities (INR >1.5 or aPTT >60s) 
(4) Thrombocytopenia (platelet count <1,00,000/µl) 
(5) Hyperbilirubinemia (plasma total bilirubin >4mg/dl) 
 
(f) Tissue perfusion parameters- 
(1) Hyperlactatemia (>3mmol/l) 
(2) Decreased capillary refill. 
 
Sepsis –definition3 
 In 2014, the European society of Intensive Care Medicine and the Society 
of Critical Care Medicine organized a task force to update the definitions and 
clinical criteria of sepsis and gave a new definition. Henceforth, the results were 
published in February 2016 issue of JAMA, the Journal of American Medical 
Association. 
 
 Also, in this conference reduced the clinical stages from 4 to 2 (singer et al, 
2016) (two stages- sepsis, septic shock) 
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 Defined sepsis as a life threatening organ dysfunction caused by a 
dysregulated host response to infection.18, 19 
 
 This new definition is being widely used in recent clinical practice. 
 
 Septic shock is sepsis with underlying circulatory and metabolic 
abnormalities. 
 
Screening for sepsis- 
q SOFA scoring system (quick sequential organ failure assessment) 20 
It includes:- 
(1) Altered Mental Status (GCS score <15) 
(2) Systolic blood pressure < or = 100mmHg 
(3) Respiratory rate > or = 22breaths per minute 
 
 SOFA scoring system is used to determine the sepsis related organ 
dysfunction. It calculates the level of dysfunction in 5 systems namely respiratory, 
cardiovascular, coagulation, renal and neurological systems. It is calculated at 
admission in every 24hrs.  
 
 According to sepsis consensus conference 2016 definition, sepsis can be 
diagnosed, if there is suspected or documented infection and an acute increase of 
>or= 2 SOFA points.21 
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Blood Stream Infections- 
 Blood stream infections are infections caused by the presence of viable 
bacterial or fungal microorganism in the blood stream showing positivity of one 
or more blood cultures and also accompanied by an inflammatory response 
characterized by alteration of clinical, laboratory and hemodynamic parameters.  
Blood stream Infections can be either primary or secondary infections. 
 
 Primary blood stream infection is an infection where there is no 
identifiable source. 
 
 Whereas secondary blood stream infection is an infection seeded from a 
site specific infection at another body site. In other words there is an identifiable 
source such as urinary tract, respiratory tract, genitourinary tract, intraabdominal 
infections etc... 
 
 Blood stream infections are traditionally classified as nosocomial or 
community onset blood stream infections. 
 
 Community onset blood stream infections are those identified less than 
48hrs of hospital admission and may be further sub-classified as health care 
associated and community acquired blood infections. 
 
 Health care associated infections are those infections detected within 
48hrs of hospital admission, showing positive blood culture and have to fulfill any 
one of the following criteria- 
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(a) Received intravenous medical therapy in any form or wound care in 30  
(b) days before the blood stream infection either at home or in any health care 
facilities. 
(c) Visited a hospital or haemodialysis clinic in 30 days before blood stream 
infection onset. 
(d) Being hospitalized in health care facility for two days or more within 90 
days before onset of blood stream infection. 
(e) Resided in a nursing home or long term health care facility. 
 
 Community acquired blood stream infections are defined as infections 
detected within 48 hrs of hospital admission, showing positive blood culture and 
those who do not fit into the criteria of health care associated infection as 
mentioned above.22 
 
Risk Factors: 
 The following are the risk factors associated in lesser frequency compared 
to nosocomial infections 23, 24 
 
a. Demographics 25, 26 
 Elderly age group 
 Males are at increased risk than females 
b. Underlying diseases 
 Diabetes mellitus 
 Hypertension 
 Chronic liver disease 
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 Chronic kidney disease 
 Chronic obstructive pulmonary  disease 
 Malignancy 
 Stroke 
c. Co-Morbid conditions 
 Smoking 
 Alcohol uptake 
 Neutropenia 
 Use of steroids 
 History of transplantation 
 
Sources of infections 1 
 Urinary tract 
 Respiratory tract 
 Intra abdominal infections 
 Biliary tract 
 Skin and soft tissue infections 
 Unknown sources 
 
Microbiology 
 Escherichia coli, Staphylococcus aureus, Streptococcus  pneumoniae are 
the commonest  causative agents 27,28 
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Other less frequent causative agents 
- klebsiella  pneumoniae 
- Salmonella spp. 
- Proteus spp. 
- Pseudomonas aeruginosa 
- Enterobacter spp. 
- Serratia spp. 
- Citrobacter spp. 
                                  
Other rare etiologies- 
- Morganella spp. 
- Providencia spp. 
 
Other Gram positive cocci- 
- Streptococcus  pyogenes 
- Streptococcus agalactiae 
- Enterococcus  faecalis 
 
These are rarely isolated or restricted to particular geographical area only. 
E.g. Brucella spp, Burkholderia pseudomallei.29 
 
Candida spp- 
- Occasional cause of community onset blood stream infections and are 
typically associated with health care associated infections. 
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CONS (Coagulase Negative Staphylococcus aureus)- 
- Predominantly related to health care associated infections and less 
frequently isolated in community onset blood stream infections. 
 
Pathogenesis- 
 Bloodstream infection is a highly complex and life threatening clinical 
entity in which pathogenesis is multifactorial. 
 
 Bacteraemia results from imbalances in the complex interplay between the 
invading microorganism and the defense mechanisms of the host. 
 
Following are the host defense mechanisms-30 
a) Innate immune mechanisms- 
 Innate immune cells generally recognize the microorganisms by sensing 
common microbial structures known as pathogen associated molecular 
patterns(PAMPS) eg-lipopolysaccharides. 
 
 Receptors on surface of immune cells called pattern recognition receptors 
recognize and attach these PAMPS. 
 
 Toll-like receptor is an important family of pattern recognition receptors 
(PRRs) and has a major role in host defense mechanism against microorganisms. 
 
 Attachment of PRRs to their ligands leads to activation of transcription 
factors e.g.- nuclear factor kappa β, that in turn leads to the production of 
proinflammatory cytokines like TNFα,IL1,IL2,IL6,IL8,IFγ. 
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 These are the general mechanism of innate immune system in host defense. 
 
Components of innate immune system which renders the function- 
Barriers, innate immune cells.  
Barriers-first barrier to pathogen invasion is skin and mucous membrane. 
 
 Microbes commonly enter the body through skin and mucosa of 
gastrointestinal tract and respiratory tract. Following which antigen presenting 
cells residing in the epithelium mainly dendritic cells, capture these microbial 
antigens and present them to naive T-lymphocytes which then differentiate to 
effector cells and then destroy these microbes. Hence, loss of skin and mucosal 
barrier leads to microbial invasion and infection. 
 
 Another potent and important barrier to pathogen invasion is the 
complement system. 
 
 Following bacterial infection, complement gets activated through classical, 
alternative or mannose binding lectin pathway and helps in pathogen destruction. 
 
 Any defect in any of these pathways leads to invasive infections. 
 
 Cellular innate immune response- neutrophils are the most important 
cellular host defense against invading pathogens. 
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 They rapidly migrate from blood to the site of infection which is mediated 
by chemo attractants like IL8, LTB4 etc... and then recognize and phagocytose the 
invading microorganisms. 
 
 Microorganisms contained in the phagosomes are killed further by 
NADPH oxidase dependent and myeloperoxidase dependent reactive oxygen 
species or by antimicrobial peptides of cytoplasmic granules. 
 Hence, neutrophils play a major role in control and in the clearance of 
invading microorganisms. 
 
 Congenital disorders or acquired deficiencies in number or functions of 
neutrophils predisposes to invasive infections both by Gram positive and Gram 
negative bacteria and also by fungi. 
 
 Other cells involved in phagocytosis include- tissue macrophages, dendritic 
cells, and natural killer cells. 
 
 Role of natural killer cells in bacteraemia and sepsis is significant. 
Increased apoptosis of natural killer cells takes place during transition from sepsis 
to severe sepsis or septic shock in patients with bloodstream infections. 
  
b) Adaptive immune response- 
 Adaptive immune response stimulated later during infection process 
includes B cell and T cell responses. 
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 T cell response- presentation of exogenous antigens or microbes to T- 
lymphocytes by antigen presenting cells via MHC-I or II dependent manner which 
in turn leads to production of pro-inflammatory cytokines critical for the clearance 
of invading microorganisms. 
 
 B cell response- results in production of antibodies against specific 
antigenic components of a certain pathogen. Antibodies interact with the 
pathogen, hence neutralizing their effect and limiting microbial infectivity. 
 
 Hence, defect in either T or B cell leads to detoriation of adaptive immune 
response and flaring up of infection and septicaemia.  
 
 Liver and spleen also plays a major role in host defense. Liver function as 
filters of bacteria from bloodstream and spleen, a major site of antibody 
production.  
 
 Hence any defect or damage to these organs will affect the host defense 
mechanism leading to microbial invasion and infections. 
 
 In pathophysiology of sepsis, in addition to above mechanisms, there 
occurs an abnormality in the coagulation system which causes local disturbances 
in hemostasis. 
 
 Virchow’s classic triad includes- changes in coagulability, endothelial cell 
injury, and abnormal blood flow. 
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 In sepsis, all 3 alterations are seen which results in reduced blood flow to 
vital organs and hence poor tissue perfusion to vital organs with resulting 
cytopathic hypoxia leads to multiorgan failure and dysfunction.31 
 
The above changes in pathophysiology of sepsis is explained further as follows- 
 At the cellular level, sepsis is characterized by changes in endothelium, 
alterations in coagulation process and in blood flow. 
 
 These changes are initiated by the cellular release of pro- inflammatory 
substances such as cytokines, in response to the presence of infectious 
microorganisms. 
 
 These pro- inflammatory cytokines are short- lived regulatory proteins 
which interact with the endothelial cells causing injury to the endothelium and 
death of endothelial cells by apoptosis. 
 
 These interactions between pro- inflammatory substances and endothelial 
cells results in activation of coagulation factors. 
 
 Endothelial damage leads to increased vascular permeability and leaky 
blood vessels. 
 
 Hence, the fluids and microorganisms escape into the surrounding tissues 
leading to edema. 
 
 In lungs, it results in pulmonary edema. Cytokines also causes 
vasodilatation of the blood vessels, causing a decrease in blood pressure. 
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 This endothelial damage resulting from inflammatory response explains the 
systemic nature of sepsis.  
 
Diagnosis- 
a) Blood culture- 
 Even though several advanced and newer techniques are upcoming, blood 
culture still remains the gold standard in diagnosis of bloodstream infections. 
 
Indications of blood culture- 
Fever with chills or of unknown origin 
Septic shock 
Leucocytosis 
Suspected endocarditis 
Pneumonia 
Meningitis 
Peritonitis 
 
Timing of blood culture specimen collection- prior to antimicrobial therapy 
initiation32 
 Volume of blood sample collected definitely has an impact on the yield - 
The higher the volume of blood cultured, the higher will be the yield and the rate 
of detection of bloodstream infections.33, 34 
 
 Incubation time- incubated for a maximum duration of 5-7days. 
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b) Biomarkers of sepsis- 
1) CRP (C-reactive protein)- 
 It is a significant marker of both inflammation and infection 
 
 It is an acute phase reactant protein belongs to pentraxin family of proteins. 
Members of these family posses a cyclic pentamer composed of five identical 
non-glycosylated polypeptide subunits which are non-covalently bound and well 
organized as a stable discoid like structure. 
 
 It is synthesised in liver by hepatocytes, chiefly in response to IL6 and 
there is often a good correlation exists between CRP and IL6. 
 
 It is also produced in small amounts by non-hepatic cells such as neurons, 
monocytes, atherosclerotic plaques, kupffer cells, lymphocytes, alveolar 
macrophages, kidneys. 
 
 It has a half life of 19hrs.35 
 
 CRP secretion begins within 4-6hrs of exposure to a stimulus and peaks at 
36-48hrs. 
 
 Serum concentration of CRP in normal healthy adult population ranges 
between 0.3-1.7mg/l   and is below 10mg/l. 
 
 Mild changes in CRP levels-vigorous exercise, heat stroke etc... 
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 Marked rise in CRP levels-acute bacterial infections, systemic fungal 
infections and in other invasive infections. 
 
 Main role of CRP-is to provide clearance of inappropriate materials of 
extrinsic origin such as microorganisms and their products or the autologous 
products of cell damage and death from plasma. 
 
Methods of measurement of CRP- 
 Latex agglutination test- initially qualitative measurement done followed 
by semi-quantitative measurement. 
 
 Several immunological methods- enzyme immunoassay, immune-
turbidimetry, nephelometry. 
 
 Applications- it has wide applications in the diagnosis of infectious 
diseases and also as a prognostic indicator not only in adults but also used as a 
marker of early onset sepsis in paediatric population as well. 
 
 It’s currently widely used in rheumatology and transplantation medicine. 
Its application in the field of cardiology is also increasing especially in coronary 
artery disease in the form of hs-CRP (highly selective CRP) 36 which is being used 
as a tool for cardiac risk evaluation and as a prognostic factor in acute coronary 
syndrome. 
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2) IL-6 (Interleukin-6)- 
 It is a multifunctional cytokine which belongs to the IL6 family. 
 Human IL-6 consists of 184 amino acids with 2 potential N-glycosylation 
sites and 4 cysteine residues. 
 It is produced by various cells such as T cells, B cells, monocytes, 
endothelial cells, fibroblasts, mesangial cells, keratinocytes, several tumour 
cells, astrocytes, bone marrow stroma cells. 
 IL6 receptors exists in 2 forms- a soluble IL6 receptor(s IL6R) and a 
membrane bound IL6 receptor (m IL6R). 
 IL6 Trans -signalling is mediated through s IL6R by activating cells that 
express gp130. 
 Classic signalling is mediated through m IL6R. 
 
Mechanism of action- 
 IL6 on binding to IL6R results in either homo or heterodimerization of 
gp130 subunit and leads to the formation of IL6/gp130 complex. 
 This complex in turn activates Janus tyrosine kinase /signal transducer and 
activator of transcription (STAT) pathway (JAK-STAT pathway). 
 IL6 has various pleiotropic functions, 37 of which salient ones are as 
follows-  
o B cells- Ig production 
o T cells- proliferation and differentiation 
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o Hematopoietic progenitor cells- enhancement of multipotential 
hematopoietic colony formation. 
o Hepatocytes-acute-phase protein synthesis. 
o Blood vessels- proliferation of vascular smooth muscle cells. 
o Bone metabolism- stimulation of osteoclast formation and induction 
of bone resorption. 
o Heart muscle cells- negative ionotropic effect on heart. 
o On placenta- secretion of chorionic gonadotropin from trophoblasts. 
 
IL6 and acute phase response-  
 Acute phase response is the response exhibited by the organism to 
disturbances in homeostasis resulting from infection, tissue damage, 
immunological disorders or any neoplastic growth, trauma or surgery.38 
 
IL6 and CRP- 
 IL6 is the main mediator stimulating CRP production, but other cytokines 
like IL1 and TNF are also involved.  
 
Antimicrobial resistant organisms in community settings-  
 Antimicrobial resistant organisms such as extended-spectrum β-lactamases 
producing Enterobacteriaceae especially E.coli, Methicillin-resistant 
Staphylococcus aureus have emerged as an important etiological agents of 
community-onset bloodstream infections. 
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 During late 1990’s and 2000 ESBL producing Enterobacteriaceae mostly 
E.coli strains have been identified predominantly from the community. 
 
 ESBL producing E.coli has gained worldwide recognition as a significant 
group of community acquired pathogen.6 
 
 Most patients with community onset infections caused by these ESBL 
producing E.coli presents with urinary tract infections, some with intraabdominal 
infections and concomitant bacteraemia. 
 
 Since mid 1990’s prevalence of community acquired methicillin-resistant 
Staphylococcus aureus (CA-MRSA) infections also started increasing. Recently 
its prevalence is around 39%.39 
 
 An awareness of these strains by the clinicians and enhanced testing by the 
laboratories, including molecular characterization and surveillance is required in 
order to frame strategies to curtail these resistant strains from spreading within the 
community and to limit their introduction into hospitals and to reduce treatment 
failures. 
 
Epidemiology- 
 There is an increase in incidence rate of bloodstream infections which is 
evident from a study done between 2008 -2014, about 14% increase from 174 in 
2008 to 197 per 1,00, 000 population in 2014. 40 
 
26 
 
 Increase in number of bloodstream infections observed among individuals 
>= 65yrs in another study, from 119 to 144 episodes per 100 000 population. 
 
 Significant increase in bloodstream infections observed in emergency 
departments in a study, from 58 to 79 per 100 000 population. 
 
 Incidence of sepsis and septic shock was around 101.8 and 19.3 per 100 
000 persons-years respectively in 2015.41 
 
 In United States, incidence of severe sepsis- 300 cases per 100 000 
population.42 
 
 Bacteraemia is a serious condition associated with a case fatality rate of 20-
30%.1, 2 
 
 Overall mortality of the patients with community acquired bloodstream 
infections ranges between 39-42% 
 
 Prevalence of community acquired bloodstream infections ranges between 
7-9%. 
 
 Overall mortality of sepsis syndrome ranges between- 20-60%43 
 
 Septic shock associated with mortality of nearly 50%.44 
 
 According to CDC data reports, more than 1.5 million people get sepsis 
each year in the U.S.  
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 About 2, 50,000 Americans die from sepsis each year. 1 in 3 patients who 
die in a hospital has sepsis.45 
 
 Global mortality rate in cases with septic shock and severe sepsis are 
44.5% and 34.4% respectively.46 
 
Prognostic factors and outcome- 
 Patients admitted in ICU with community acquired bacteraemia presents 
with a crude mortality near to 40% compared with a mortality of 18% in 
bacteraemia patients admitted in general wards. 
 
Prognostic factors responsible for outcome of patient- 
 Age 
 Severity of patient’s underlying disease 
 Source of infection 
 Type of organism involved 
 Complications and associated co-morbidities 
 Appropriateness of empiric antimicrobial treatment 
 Associated secondary infections. 
 Mortality among patients with inappropriate empiric antibiotic treatment is 
around >70%.47 
  
28 
 
 
Complications- 
1. Septic shock 
2. End organ dysfunctions- 
a) Lungs-acute respiratory distress syndrome 
b) Brain-encephalopathy 
c) Liver failure  
d) renal failure  
e) Heart failure 
 
Prevention of sepsis- 
 As per CDC recommendations, the health care professionals should take 
following measures to prevent sepsis-48 
 
1. Prevention of infection by following infection control practices like proper 
hand washing protocols & ensure that patient gets recommended vaccines. 
(E.g. influenza, pneumococcal). 
2. To educate patients & their families on the need to prevent infections. 
3. If sepsis is suspected, need to act faster by ordering tests which will detect 
sepsis early. To start appropriate antibiotics and recommended medical care 
immediately. Also, to document all aspects of the antibiotic regimen. 
 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
Study design : Cross-sectional study. 
Study centre  :      Institute of Microbiology, in collaboration with 
    Institute of Internal Medicine and Surgery,  
    RGGGH, MMC,  Chennai. 
 
Duration of study : 1 year (from March 2017- February 2018) 
 
Sample size  :  150  
Study population:  
 Febrile adult patients with sepsis admitted within 48hrs in Medicine wards, 
Intensive Care Unit and Surgical wards at Rajiv Gandhi Government General 
Hospital.  
 
ETHICAL CONSIDERATION-  
 Ethical clearance was obtained from Institutional Ethics Committee before 
starting the study. Informed consent was obtained from the study population. 
Patients those who where satisfying the inclusion criteria were included in this 
study. Study population was interviewed by a structured questionnaire. 
 
INCLUSION CRITERIA: 
1. Febrile patients in the age group >18 years. 
2. Patients with sepsis admitted to hospital within 48hrs. 
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EXCLUSION CRITERIA: 
1. Patients in the age group <18 years. 
2. Patients with signs and symptoms of sepsis developed after 48hrs of 
hospitalization. 
3. Patients already on antibiotic therapy.  
 
METHODOLOGY 
a) BLOOD COLLECTION PROCEDURE- 
 Under strict aseptic precautions, the skin over the venipuncture site was 
cleansed in a circle approximately 5cm in diameter with 70% isopropyl alcohol 
rubbing vigorously and allowed to air dry.49 Then applied 2% povidone-iodine 
starting in the centre of the circle then moved towards periphery and allowed it to 
dry on the skin for at least one minute. The needle was then inserted into the 
selected appropriate peripheral vein and about 5ml blood sample was collected for 
processing and culture identification.  
 
b)  SAMPLE PROCESSING- 
 The blood sample was inoculated into brain heart infusion broth and 
incubated overnight at 37℃. These inoculated bottles were examined after 24hrs 
for any turbidity, discoloration or clotting. The first subculture was done on to 
MacConkey agar, blood agar, chocolate agar and sabouraud dextrose agar and 
incubated overnight at 37℃ and also a Gram film was performed. These bottles 
were again incubated and checked for turbidity twice daily. A final subculture was 
done on seventh day on the same medias mentioned above and also a Gram film 
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was performed. The blood culture was considered negative if no growth occurred 
even on the seventh day of subculture i.e. final subculture. Any growth which 
occurred during this seven day period of incubation was identified based on Gram 
stain, colony morphology and various biochemical reactions.  
 
Direct Gram Film- 
 Gram film was examined as soon as the subcultures had been setup and 
interpreted. 
 
Examination of subcultures- 
 After 24 hrs of incubation, the subcultured plates were examined. If growth 
was found, the colony morphology was recorded. Then, further the colonies were 
identified by – 
a) Gram stain- to identify Gram positive or Gram negative organisms. 
b) Motility test by hanging drop method- to identify whether the organism is 
motile or non-motile. 
c) Other preliminary tests- catalase test, oxidase test were also performed 
d) Organisms further speciated based on biochemical reactions- IMVic 
reactions (includes- indole test, methyl red test, Voges-proskauer test and 
citrate test), urease test, triple sugar iron agar test medium and the sugar 
fermentation medium. 
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CULTURE IDENTIFICATION- 
a) Staphylococcus aureus- 
Nutrient agar- Showed 1 to 3mm diameter, circular, smooth, low convex, 
glistening densely opaque colonies with golden yellow pigmentation. 
 
Blood agar- Colonies were surrounded by a narrow zone of beta hemolysis. 
 
MacConkey agar- Colonies were pink and were smaller in size. 
 
Organisms confirmed with biochemical reactions. 
1. Slide coagulase test- in a clean grease free glass slide, a colony of test 
organism was emulsified in a drop of normal saline to form a smooth milky 
suspension. To this suspension, a drop of plasma was added and the slide was 
rotated back and forth. Coarse clumping of the suspension visible to the naked 
eye within 10 seconds was considered positive and absence of clumping as 
negative. The test was performed with appropriate controls. 
2. Tube coagulase test- to 0.5ml of diluted plasma (1 in 6 dilutions in 0.85% 
Nacl), a colony of Staphylococcus was emulsified in a tube and incubated at 
37℃ for 4hrs preferably in a water-bath along with appropriate controls. 
Examined the tubes at 1, 2 and 4hrs for clot formation by tilting the tube 
through 90⁰. Any degree of clot formation was considered positive. If the 
plasma remained as wholly liquid, it was considered as negative.50 
Both slide and tube coagulase tests were found positive. 
  
33 
 
BIOCHEMICAL REACTIONS- 
Indole test Negative 
Methyl red test Positive 
Voges-proskauer test Positive 
Mannitol Fermented 
Urease test Positive 
 
Hence, with above findings, identified as Staphylococcus aureus. 
 
Escherichia coli- 
Nutrient agar- Colonies were 1-3mm diameter, circular, low convex, 
smooth colonies with no pigmentation or odour. 
Blood agar- Greyish white colonies with hemolysis. 
MacConkey agar- Flat, pink, lactose fermenting colonies. 
 
BIOCHEMICAL REACTIONS- 
Indole test Positive 
Methyl red test Positive 
Voges proskauer test Negative 
Citrate Negative 
Glucose Fermented with acid & gas 
Lactose Fermented with acid & gas 
Sucrose Not fermented 
Maltose Fermented with acid & gas 
Mannitol Fermented with acid & gas 
TSI Acid slant/Acid butt with gas & no H₂S 
Urease test Negative 
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Pseudomonas aeruginosa51 
Nutrient agar- colonies were large, low convex with serrated margins with bluish 
green pigmentation and earthy odour. 
Blood agar- diffuse hemolysis was present. 
MacConkey agar- Non-lactose fermenting colonies. 
Indole test negative 
Methyl red test negative 
Voges- proskauer test negative 
Citrate utilized 
Glucose Oxidatively utilized 
Lactose Oxidatively utilized 
Mannitol Not fermented 
Xylose Oxidatively utilized 
TSI Alkaline slant/no change in the butt 
OF test Oxidative pattern 
Urease test positive 
 
Acinetobacter baumannii 51 
Blood agar- smooth, opaque, raised colonies 
MacConkey agar- non-lactose fermenting colonies with a faintly pink tint. 
Indole test negative 
Citrate utilized 
Glucose Not fermented 
TSI Alkaline slant/no change in the butt 
10% OF lactose Oxidatively utilized 
Urease test negative 
Growth at 42℃  Good growth 
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Antimicrobial susceptibility testing for isolated organisms done on Mueller 
Hinton agar plate by Kirby- Bauer disk diffusion method under CLSI guidelines. 
 
PROCEDURE FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING- 
1) Preparation of turbidity standard equivalent to McFarland 0.5: 
a)  1% v/v solution of sulphuric acid was prepared by adding 1ml of 
concentrated sulphuric acid to 99ml of distilled water and was mixed well. 
b)  1% w/v solution of barium chloride was prepared by dissolving 0.5 g of 
dihydrate barium chloride in 50ml of distilled water and was mixed well. 
c)  0.6 ml of barium chloride solution was added to 99.4 ml of sulphuric acid 
solution and was mixed well. This mixture was transferred into a screw 
capped tube which could be used during inoculum preparation. 
 
2) METHOD- 
a) Using a sterile loop, 3-5 well- isolated colonies of test organism, of similar 
appearance were inoculated into 3-4ml of nutrient broth and emulsified it. 
b) The turbidity of the above suspension was matched with the turbidity 
standard equivalent to 0.5 under good light and viewed against a printed 
card or sheet of paper. 
c) Within 15 minutes after adjusting the turbidity of the inoculum, a sterile 
cotton swab was dipped into the adjusted suspension, rotated several times 
in it and then pressed firmly on the wall of the tube above the fluid level to 
remove excess inoculum from the swab. 
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d) Using this swab streaking was done evenly over the surface of Mueller 
Hinton agar medium in three directions, by rotating the plate 
approximately 60⁰, to ensure for even distribution of the inoculum.  
e)  3-5 minutes waited for the surface of the agar to dry. 
f) Then the appropriate antimicrobial discs were placed, distributed evenly on 
the inoculated plate. 
g) Within 30 minutes of applying the antimicrobial discs, the plate was 
inverted and incubated aerobically at 35℃ for 16-18hrs. 
h) After overnight incubation, the diameter of the zone of inhibition was 
measured in mm using a ruler on the underside of the plate. 
i) Interpretation of zone size- using the interpretative charts, containing the 
zone sizes of each antimicrobials, as per CLSI guidelines, organisms were 
reported to be susceptible, intermediate or resistant to the particular 
antimicrobial drug. 
j) Appropriate controls were used with each batch during this susceptibility 
testing. 
1. Escherichia coli- ATCC 25922 
2. Pseudomonas aeruginosa- ATCC 27853 
3. Staphylococcus aureus- ATCC 25923 
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PROCEDURE FOR DETECTION OF METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS (MRSA)- 
 Using the differential disk, Cefoxitin (30µg), Staphylococcus aureus 
isolates were categorized into methicillin sensitive and methicillin resistant 
strains.52 
 
Cefoxitin(30µg) Susceptible Intermediate Resistant 
Zone size >=22mm - < or =21mm 
 
VANCOMYCIN SUSCEPTIBILITY TESTING AND MIC DETECTION 
PROCEDURE- 
 Vancomycin sensitivity was tested using Vancomycin screen agar (BHI 
agar with 6µg/ml of Vancomycin), where 10µl of bacterial suspension was spot 
inoculated onto this media and incubated overnight at 37℃ along with appropriate 
controls.52 
 
After 24hrs of incubation, the sensitivity pattern was interpreted as follows- 
1. If no visible growth at spot inoculated site- reported as sensitive to 
Vancomycin. 
2. If visible growth (> 1 colony) at spot inoculated site was present –reported 
as resistant to Vancomycin. 
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E-TEST PROCEDURE- 
 Using an inoculating loop, 4-5 isolated colonies of Staphylococcus were 
transferred to a test tube containing peptone water and emulsified. Incubated it for 
2-4hrs until the growth equal to a 0.5 McFarland turbidity standard was reached. 
A sterile cotton swab was dipped into this inoculum suspension and pressed 
against the inside wall of the tube to remove excess fluid and then streaked over 
the entire surface of Mueller Hinton agar plate evenly in three directions. The 
surface of agar was allowed to dry completely and then an E-strip was applied to 
the agar surface with the MIC scale facing upwards. The plate was then incubated 
at 37℃ for overnight incubation. After 24 hrs of incubation, the MIC value was 
read at a point where the edge of inhibition ellipse intersects the strip.52 
 
Vancomycin Susceptible Intermediate Resistant 
MIC(µg/ml) < or =2 4-8 >=16 
 
Among the Gram negative organisms identified, ESBL producers detected as 
follows- 
 
 Initial screening test done by disk diffusion method under CLSI 
guidelines using Cefotaxime (30µg) disk and Ceftazidime (30µg) disk which were 
applied on to Mueller Hinton agar plate inoculated with the test organism and 
incubated at 37℃ for 24hrs. Screening test denoted ESBL production if zone size 
was as follows- 52 
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Cefotaxime (30µg) < or =27mm 
Ceftazidime (30µg) < or =22mm 
 
Phenotypic confirmatory test done by disk diffusion method under CLSI 
guidelines by combination disk test method using cefotaxime (30µg) disk and 
cefotaxime- clavulanic acid (30µg/10µg). 
Combination disk test- Disks containing cephalosporin alone and in combination 
with clavulanic acid were applied onto Mueller Hinton agar plate inoculated with 
test organism and incubated at 37℃ for 24hrs. 
Interpretation- Inhibition zone around cephalosporin disk combined with 
clavulanic acid is >=5mm larger than the inhibition zone around the disk with 
cephalosporin alone was considered positive for ESBL. 
 
MOLECULAR METHODS- 
Characterization of resistant bacterial isolates- 
 Polymerase chain reaction was performed to detect the resistant genes. 
 
Materials required- 
 PureFast® Bacterial DNA minispin purification kit  [Kit contains 
Lysozyme, Lysozyme digestion buffer, Proteinase-K, Binding buffer, Wash 
Buffer-1, Wash Buffer-2, Spin columns with collection tube and elution buffer.   
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Other requirements-  
 2X Red Dye PCR Master Mix, Agarose gel electrophoresis consumables 
and blaTEM, blaCTX-M, mecA Primers.    
  
2X Master Mix: 
 It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1µl of 10mM dNTPs mix and RedDye PCR additives.  
 
Agarose gel electrophoresis:  
 Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide. 
 
PCR: 
 blaTEM gene Primer mix - 5µl/reaction PCR Product: 260bp  
  blaCTX-M gene Primer mix - 5µl/reaction PCR Product: 295bp  
 mecA gene Primer mix - 5µl/reaction PCR Product: 220bp  
 
EXTRACTION OF DNA- 
PROTOCOL- 
1. 1ml of overnight culture was centrifuged at 6000rpm for 5mins.  
2. Supernatant discarded  
3. Pellet was suspended in 0.2ml PBS.  
4. 180µl of Lysozyme digestion buffer and 20µl of Lysozyme [10mg/ml] were 
added.  
5. Incubated at 37⁰C for 15mins.  
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6. 400µl of Binding buffer, 5µl of internal control template and 20µl of 
Proteinase K  were added and mixed well by inverting several times.  
7. Incubated at 56⁰C for 15mins.  
8. Then added 300µl of Ethanol and mixed well.  
9. Transferred entire sample into the PureFast® spin column. Centrifuged for 1 
min. discarded the flow-through and placed the column back into the same 
collection tube.    
10. Added 500μl Wash buffer-1 to the PureFast® spin column. Centrifuged for 
30-60 seconds and discarded the flow-through. The column was placed back 
into the same collection tube.  
11. Then added 500μl Wash buffer-2 to the PureFast® spin column. Centrifuged 
for 30-60 seconds and discarded the flow-through. The column was placed 
back into the same collection tube.    
12. Discarded the flow-through and centrifuged for an additional 1 min. This 
step was essential to avoid residual ethanol.  
13. Transferred the PureFast® spin column into a fresh 1.5 ml micro-centrifuge 
tube.  
14. Then added 100μl of Elution Buffer to the center of PureFast® spin column 
membrane.   
15. Incubated for 1 min at room temperature and centrifuged for 2 mins.    
16. Discarded the column and then stored the purified DNA at -20°C.  Quality 
and Quantity of extracted DNA was checked by loading in 1% agarose gel 
and 5µl of extracted DNA was used for PCR amplification. 
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AMPLIFICATION OF DNA: 
1. Reactions were set up as follows: 
                Components                                     Quantity  
 RedDye PCR Master Mix   - 10µl  
 Primer Mix     - 5µl  
Purified Bacterial DNA  - 5µl  
Total volume    - 20µl  
  
2. Mixed gently and was spinned down briefly.  
3. Placed into PCR machine and programmed it as follows: 
  
Initial Denaturation :  95℃ for 5 mins  
Denaturation  :  94℃ for 30secs ⁆ 
Annealing   : 58℃ for 30secs ⁆    ----    35 cycles  
Extension   : 72℃for 30secs  ⁆ 
 Final extension  : 72℃ for 5 mins  
 
Loading: 
a) Prepared 2% agarose gel. [2gm of agarose in 100ml of 1X TAE buffer]  
b) Electrophoresis was run at 50V till the dye reached three fourth distances 
and observed the bands in UV Transilluminator.  
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Agarose gel electrophoresis:  
1. Prepared 2% agarose.  (2gm agarose in 100ml of 1X TAE buffer and 
melted using micro oven)  
2. When the agarose gel temperature was around 60℃, added 5µl of Ethidium 
bromide. 
3. Poured warm agarose solution slowly into the gel platform.    
4. Kept the gel set undisturbed till the agarose solidified. 
5. Poured 1XTAE buffer into submarine gel tank.  
6. Carefully the gel platform was placed into the electrophoretic tank which 
was filled with buffer at a level of 0.5cm above the gel.   
7. PCR Samples were loaded after mixed with gel loading dye along with 
10µl of 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 
700bp, 800bp, 900bp, 1000bp and 1500bp]  
8. Electrophoresis was run at 50V till the dye reached three fourth distance of 
the gel.  
9. The gel was observed under the UV Transilluminator and observed the 
bands pattern which detected the presence of DNA.  
  
44 
 
Determination of Inflammatory markers: 
 About 2ml blood sample was collected under sterile aseptic precautions 
and  allowed to clot in a dry test tube, serum separated and used for the estimation 
of inflammatory markers. 
 
1. C-Reactive protein estimation- 
 CRP estimation was done using PROTON-CRP ESTIMATION KIT-GenX 
CRP slide latex agglutination test kit. 
  
Principle- 
 The test is based on the principle of latex agglutination. CRP estimation 
was done using uniform latex particles coated with anti-human CRP.When latex 
reagent was mixed with the test serum containing CRP, at a level greater than 
0.6mg/dl, it forms visible agglutination. If the concentration of CRP lesser than 
0.6mg/dl, then no agglutination. 
 
Materials required- 
1. Anti-CRP latex reagent 
2. Positive control 
3. Negative control 
4. Others- slides, droppers, mixing sticks. 
 
Sample- serum 
 It involves-qualitative test and semi-quantitative test. 
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i) Qualitative test- 
Procedure- 
1. One drop (approx.40-50µl) of test serum sample, positive control and negative 
control was placed in separate circles of the glass slide by using the sample 
dropper. 
2. Then one drop of latex reagent was added in each of these circles with the 
dropper. 
3. The contents of each circle were mixed separately and were spread in the 
entire circle with the mixing sticks. 
4. Then the slide was rocked gently for 2 minutes and looked for any visible 
agglutination. 
5. The results should not be read after 2 minutes. 
 
Interpretation- 
Marked agglutination- CRP positive (>0.6mg/dl) 
No agglutination- CRP negative (<0.6mg/dl) 
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ii) Semi- quantitative determination- 
Procedure- 
1. The sera found positive were retested by preparing serial dilutions of the test 
sample (1:2, 1:4, 1:8, 1:16,  and so on) using 0.9% sodium chloride solution in 
clean labelled test tubes as below: 
Tube no. 1. 2. 3. 4. 5. 6. Saline control 
Serum dilution 1:2 1:4 1:8 1:16 1:32 1:64 - 
Saline 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 
Patient’s serum 0.5ml - - - - - - 
Transfer diluted 
serum from previous 
tube 
- 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml - 
 
 Each dilution was tested like the qualitative procedure until no further 
agglutination was observed. 
 
 CRP concentration was estimated for the highest dilution at which visible 
agglutination occurred and calculated by using the formula- 
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 CRP (mg/l) - highest dilution with positive reaction X reagent sensitivity 
(6mg/l) The titres for the various dilutions are as follows- 
 
DILUTION TITRE 
1:2 12mg/l 
1:4 24mg/l 
1:8 48mg/l 
1:16 96mg/l 
1:32 192mg/l 
1:64 384mg/l 
 
Estimation of Interleukin-6- 
 IL-6 was done using Human Interleukin-6 Kit, Krishgen Biosystems 
 
Principle-  
 The test is based on the principle of sandwich ELISA method which 
quantifies the target cytokine between two layers of antibodies (i.e. capture and 
detection antibody). The cytokine to be measured contains at least two antigenic 
epitope capable of binding to antibody, since at least two antibodies act in the 
sandwich. The advantage of Sandwich ELISA is that the sample does not have to 
be purified before analysis, and the assay can be very sensitive up to pg/ml levels 
(more sensitive than direct or indirect ELISA). 
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Materials required- 
1. Microtiter Coated Plate (12X8 wells)  
2. Recombinant Human IL-6 Standard  
3. Human IL-6 Biotin Conjugated Detection Antibody  
4. Concentrated Avidin Horseradish Peroxidase  
5. Wash Buffer (20X) – 25ml 
6. . Assay Diluent (5X) - 10ml 
7. Assay Diluent – 6ml (ready to use) 
8. TMB Substrate – 12ml 
9. Stop Solution – 12ml 
 
Sample-serum 
REAGENT PREPARATION- 
1. WASH BUFFER (20X): 
To make wash buffer (1X), 5ml of wash buffer (20X) added to 95ml of 
distilled water- working solution. 
2. ASSAY DILUENT (1X): 
To make assay diluent (1X), 10ml of assay diluent (5X) added to 40ml of 
distilled water- working solution. 
3. STANDARD (RECOMBINANT HUMAN-IL-6 LYOPHILIZED, 200pg/ml): 
Lyophilized Human IL-6 standard reconstituted with 650µl of distilled water 
to achieve final concentration of 200pg/ml- used as the top standard to perform 
serial dilutions. 
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4. BIOTIN CONJUGATED DETECTION ANTIBODY (50µl): 
20µl of detection antibody solution added to 4980µl of assay diluents (1X) to 
make the final volume to 5ml. 
5. CONCENTRATED AVIDIN-HRP (50µl): 
20µl of Avidin-HRP added to 4980µl of assay diluents (1X) to make the final 
volume to 5ml. 
 
ASSAY PROCEDURE- 
1. All reagents were brought to room temperature prior to use.  
2. Added 100µl/well of assay diluent (ready to use preparation) only along with 
standards which were used for serial dilutions. 
3.  Then added 100μl/well of Standards and Samples to the plate, where only 
standards were duplicated and performed two-fold serial dilutions of the 
200pg/ml top standard, within the plate. Thus, the Human IL-6 standard 
concentrations were 200pg/ml, 100pg/ml, 50pg/ml, 25pg/ml, 12.5pg/ml, 
6.25pg/ml and 3.13pg/ml. Assay Diluent (1X) served as the zero standard (0 
pg/ml). Sealed the plate and incubated for 2 hours at room Temperature (18-
25°C). 
4. Aspirated and washed the plate 4 times with Wash Buffer (1X) and blotted the 
residual buffer by firmly tapping plate upside down on absorbent paper. Wiped 
of any liquid from the bottom outside of the microtiter wells as any residue can 
interfere in the reading step. All the washes were performed similarly. 
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5. Then added 100μl of diluted Detection Antibody solution to each well sealed 
the plate and incubated for 1 hour at room Temperature (18-25°C).  
6. Washed the plate 4 times with Wash Buffer (1X) as in step 4. 
7. Added 100μl of diluted Avidin-HRP solution to each well sealed the plate and 
incubated for 30 minutes at room Temperature (18-25°C).  
8. Washed the plate 4 times with Wash Buffer (1X) as in step 4. 
9. Added 100μl of TMB Substrate solution and incubated in the dark for 30 
minutes. Positive wells turned bluish in color. No need to seal the plate during 
this step. 
10. The reaction was stopped by adding 100μl of Stop Solution to each well. 
Positive wells turned from blue to yellow.  
11. Absorbance was read at 450 nm within 30 minutes of stopping the reaction. 
 
CALCULATION OF RESULT: 
1. Using a semi-log graph paper, the optical densities of each standard were 
plotted on Y-axis and the corresponding concentration of the standards on the 
X-axis. 
2.  The best fit straight line was drawn through the standard points. 
3. To determine the unknown cytokine concentration, a horizontal line was 
drawn corresponding to the optical density obtained for each sample plotted on 
Y- axis, intersecting the standard curve. 
4. At the point of intersection, a vertical line was drawn to the X-axis and read 
the cytokine concentration which was expressed in pg/ml. 
  
51 
 
 
STATISTICAL ANALYSIS- 
 Statistical analysis for the collected data was done using SPSS software 21. 
 The demographic variables were expressed in frequency and percentage. 
 For Quantitative variables, mean and standard deviations were determined. 
 Validity of the tests were determined by calculating the sensitivity, 
specificity,   positive predictive value, negative predictive value, 95% 
confidence intervals. 
 
  
Results 
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RESULTS 
 
 The study was done during a period of 1year from March 2017- February 
2018 at Institute of Microbiology in collaboration with the Institute of Internal 
Medicine and Surgery. The study group included 150 patients in the age group > 
18yrs with clinical suspicion of sepsis admitted within 48hrs in Medical, surgical 
wards and Intensive Care Units at Rajiv Gandhi Government General Hospital. 
 
TABLE-1 
AGE DISTRIBUTION OF PATIENTS WITH SUSPECTED SEPSIS (n=150) 
 
AGE 
(yrs) NO. OF PATIENTS PERCENT 
19-29 31 20.7 
30-39 29 19.3 
40-49 41 27.3 
50-59 26 17.3 
60 & above 23 15.3 
TOTAL 150 100 
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TABLE-2 
SEX DISTRIBUTION OF PATIENTS WITH SUSPECTED SEPSIS (n=150) 
SEX NO. OF PATIENTS PERCENT 
MALE 91 60.7 
FEMALE 59 39.3 
TOTAL 150 100 
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CHART 3 
CLINICAL PROFILE OF PATIENTS WITH SUSPECTED SEPSIS (n=150) 
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RESULTS OF BLOOD CULTURE- 
 Blood culture was done in 150 patients with clinical suspicion of sepsis, 
out of which community acquired bloodstream infection was detected in 12 
patients (8%) 
 
CHART 4 
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TABLE-3 
AGE DISTRIBUTION OF PATIENTS WITH COMMUNITY ACQUIRED 
BLOODSTREAM INFECTION 
 
AGE 
(yrs) 
NO. OF PATIENTS WITH 
COMMUNITY ACQUIRED 
BSI 
PERCENT 
51-60 6 50 
61-70 4 33.3 
71-80 1 8.3 
>80 1 8.3 
Total 12 100 
 
Above table shows, majority (50%) falls under the age group 51-60yrs. 
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TABLE-4 
SEX DISTRIBUTION OF PATIENTS WITH COMMUNITY ACQUIRED 
BLOODSTREAM INFECTION 
 
SEX NO. OF PATIENTS PERCENT 
MALE 9 75 
FEMALE 3 25 
TOTAL 12 100 
 
 
CHART 6 
 
  
 Table 4 reveals that males were predominantly affected in patients with 
community acquired BSI 
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CHART 7 
ORGANISMS ISOLATED BY BLOOD CULTURE IN COMMUNITY 
ACQUIRED BLOODSTREAM INFECTION 
 
    
 
CHART 8 
WARD WISE DISTRIBUTION OF GRAM POSITIVE ISOLATES 
OBTAINED 
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CHART 9 
WARD WISE DISTRIBUTION OF GRAM NEGATIVE ISOLATES 
OBTAINED 
  
 
TABLE-5 
GRAM POSITIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED PERCENT 
Staphylococcus aureus 
(MSSA) 6 85.7 
Staphylococcus 
aureus(MRSA) 1 14.3 
Total 7 100 
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TABLE-6 
CRP LEVELS AMONG GRAM POSITIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED CRP  RANGE 
Staphylococcus aureus 
(MSSA) 6  
190-200mg/l Staphylococcus aureus 
(MRSA) 1 
 
 
TABLE-7 
IL-6 LEVELS AMONG GRAM POSITIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED IL-6 RANGE 
Staphylococcus aureus 
(MSSA) 6  
 
300-900 pg/ml Staphylococcus aureus 
(MRSA) 1 
 
Tables-5,6&7 depicts that among Gram positive organisms detected, 
85.7% were MSSA and 14.3% were MRSA isolates with CRP conc. ranged 
between 190-200mg/l and IL-6 conc. ranged between 300-900pg/ml.  
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TABLE-8 
GRAM NEGATIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED PERCENT 
E.coli 3 60 
Pseudomonas aeruginosa 1 20 
Acinetobacter baumannii 1 20 
Total 5 100 
 
 Above table shows among the Gram negative organisms isolated, E.coli 
contributes 60%, Pseudomonas aeruginosa and Acinetobacter baumannii 
contributes each 20% respectively. 
  
TABLE-9 
CRP LEVELS AMONG GRAM NEGATIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED CRP RANGE 
E.coli 3 
 
190-400 mg/l Pseudomonas aeruginosa 1 
Acinetobacter spp. 1 
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TABLE-10 
IL-6 LEVELS AMONG GRAM NEGATIVE ORGANISMS 
 
ORGANISMS NO. ISOLATED IL-6 RANGE 
E.coli 3 900-1200 pg/ml 
Pseudomonas aeruginosa 1 1000-1200 pg/ml 
Acinetobacter baumannii 1 600-800 pg/ml 
 
 
TABLE-11 
RESISTANT STRAINS AMONG GRAM NEGATIVE ORGANISMS 
 
CHARACTERS VALUE 
Total Gram negative bacilli 5 
Resistant strains (ESBL producers) 3 
Percentage of resistant strains among 
Gram negative bacilli 60% 
 
 From above table, Among the Gram negative organisms isolated, 60% 
were ESBL producers. 
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TABLE-12 
CRP & IL-6 LEVELS AMONG RESISTANT STRAINS 
 
 
TABLE-13 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN AMONG GRAM 
POSITIVE ORGANISMS 
ORGANISM 
METHICILLIN 
SENSITIVE 
STAPHYLOCOCCUS 
AUREUS (MSSA) 
METHICILLIN 
RESISTANT 
STAPHYLOCOCCUS 
AUREUS (MRSA) 
NUMBER 
ISOLATED 6 1 
DRUGS S (%) R (%) S (%) R (%) 
Ciprofloxacin 50 50 100 0 
Penicillin 100 0 0 100 
Cotrimoxazole 33.3 66.7 0 100 
Erythromycin 100 0 100 0 
Linezolid 100 0 100 0 
Tetracycline 100 0 0 100 
Vancomycin 100 0 100 0 
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TABLE-14 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF GRAM NEGATIVE 
ORGANISMS 
 
ORGANISM ESCHERICHIA COLI 
PSEUDOMONAS 
AERUGINOSA 
ACINETOBACTER 
BAUMANNII 
NO. 
ISOLATED 3 1 1 
DRUGS S (%) R (%) S (%) R (%) S (%) R (%) 
Amikacin 100 0 100 0 0 100 
Gentamicin 33.3 66.7 100 0 0 100 
Ciprofloxacin 0 100 100 0 0 100 
Cotrimoxazole 0 100 - 0 100 
Ampicillin 0 100 - - 
Cefotaxime 0 100 - - 
Cefotaxime-
clavulanic acid 100 0 - - 
Ceftazidime 0 100 0 100 0 100 
Tetracycline 100 0  100 0 
Piperacillin-
Tazobactum  100 0 100 0 
Imipenem - 100 0 100 0 
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TABLE-15 
CO-MORBIDITIES AND RISK FACTORS ASSOCIATED WITH BSI IN 
THIS STUDY 
 
CO-MORBIDITIES 
AND  RISK FACTORS NO. OF PATIENTS PERCENT 
DIABETES 9 75 
HYPERTENSION 4 33.3 
SMOKING 3 25 
ALCOHOLISM 4 33.3 
ANAEMIA 7 58.3 
 
CHART 10 
  
 
 Table 15 shows that diabetes mellitus (75%) and anaemia (58.3%) were the 
predominant risk factors. 
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TABLE-16 
PRIMARY SYSTEM INVOVEMENT IN COMMUNITY ACQUIRED BSI 
PATIENTS 
 
SYSTEM INVOVLED NO. OF PATIENTS PERCENT 
RESPIRATORY 8 66.7 
INTRAABDOMINAL 2 16.7 
RENAL 1 8.3 
SKIN AND SOFT TISSUES 1 8.3 
TOTAL 12 100 
 
 Respiratory system was the predominant primary system involved (66.7%) 
in patients with community acquired BSI. 
 
TABLE-17 
HEMATOLOGICAL PARAMETERS IN BLOOD CULTURE NEGATIVE 
CASES 
 N Minimum Maximum Mean 
Std. 
Deviation 
Hemoglobin 138 8.5 16.4 11.888 1.3862 
Total count 138 3400.0 18200.0 13134.058 2606.9110 
ESR 138 10.0 28.0 17.717 3.8341 
MCV 138 71.4 92.9 82.915 4.4553 
MCH 138 23.6 34.6 27.693 2.1381 
MCHC 138 29.6 38.5 32.950 1.4017 
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TABLE-18 
HEMATOLOGICAL PARAMETERS IN BLOOD CULTURE POSITIVE 
CASES 
 N Minimum Maximum Mean 
Std. 
Deviation 
Hemoglobin 12 8.4 13.0 10.150 1.4619 
Total count 12 18600.0 23800.0 21600.000 1616.3933 
ESR 12 22.0 28.0 24.750 1.7645 
MCV 12 74.2 102.2 80.408 7.8102 
MCH 12 23.3 42.6 28.192 5.6250 
MCHC 12 29.8 36.2 31.750 1.8103 
 
 
TABLE-19  : PLATELET COUNT 
 
PLATELET COUNT FREQUENCY PERCENT 
NORMAL 124 82.7 
ABNORMAL 26 17.3 
TOTAL 150 100 
 
Table 17, 18, 19 shows correlation statistically significant with a p value 0.05. 
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TABLE-20 
C-reactive protein (CRP) & Blood culture positivity 
 
CRP conc. range 6-10 mg/l 11-70mg/l 90-190mg/l 
190-400 
mg/l 
CRP 32 (21.3%) 
90 
(60%) 
16 
(10.7%) 
12 
(8%) 
BLOOD CULTURE 
POSITIVE - - - 12 
 
TABLE-21 
IL-6 & BLOOD CULTURE POSITIVITY 
 
IL-6 conc. range 3-11 pg/ml 12-60pg/ml 
70-
120pg/ml 
200pg/ml 
&above 
IL-6 52 (34.7%) 
28 
(28.6%) 
58 
(59.2%) 
12 
(12.2%) 
BLOOD CULTURE 
POSITIVE - - - 12 
 
 Table 20, 21- depicts that both CRP and IL-6 levels were found elevated in 
blood culture positive patients (correlation significant with a p value 0.01). 
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TABLE-22 
OUTCOME OF PATIENTS WITH COMMUNITY ACQUIRED BSI 
 
OUTCOME FREQUENCY PERCENT 
RECOVERED 9 75 
EXPIRED 3 25 
TOTAL 12 100 
 
 Among 12 patients with community acquired BSI, 9 patients (75%) got 
recovered and 3 patients (25%) expired.  
 
CHART 11 
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TABLE-23 
CRP & IL-6 LEVELS AND OUTCOME OF PATIENTS WITH 
COMMUNITY ACQUIRED BSI 
 
CRP RANGE IL-6 RANGE OUTCOME 
300-400mg/l 900-1200pg/ml Expired(3) 
190-200mg/l 400-800pg/ml recovered 
 
TABLE-24   OUTCOME IN CULTURE NEGATIVE CASES 
 
TABLE-25     CRP POSITIVITY 
CRP FREQUENCY PERCENT 
POSITIVE 118 78.7 
NEGATIVE 32 21.3 
TOTAL 150 100 
 
  
SIRS CRITERIA FULFILLED 
BUT CULTURE NEGATIVE 
CRP 
RANGE 
IL-6 
RANGE OUTCOME 
136(98.6%) 6-100mg/l 3-96 pg/ml recovered 
2(1.4%) 90-200mg/l 80-120pg/ml expired 
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TABLE-26        IL-6 POSITIVITY 
IL-6 FREQUENCY PERCENT 
POSITIVE 103 68.7 
NEGATIVE 47 31.3 
TOTAL 150 100 
 
TABLE-27 
COMPARISON OF IL-6 WITH CRP AS BETTER EARLY SEPSIS 
MARKER 
IL-6 Vs CRP ESTIMATED VALUE 95%CONFIDENCE INTERVAL 
SENSITIVITY 83% 75%-89% 
SPECIFICITY 84% 66%-94% 
POSITIVE 
PREDICTIVE VALUE 95% 88%-98% 
NEGATIVE 
PREDICTIVE VALUE 57% 42%-71% 
 
 Above table27 shows that IL-6 was both sensitive and specific early 
biomarker of sepsis than CRP in this study. 
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TABLE-28 
AREA UNDER THE CURVE FOR IL-6 AND CRP 
 
TEST VARIABLES AREA UNDER THE CURVE 
IL-6 67% 
CRP 61% 
 
CHART 12  
 
Table 28 shows that area under the curve for IL-6 was more than the CRP. 
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TABLE-29 
MORTALITY PREDICTION IN PATIENTS WITH COMMUNITY 
ACQUIRED SEPSIS WITH IL-6 CONCENTRATION- 
 
TEST VARIABLE MEAN ESTIMATED VALUE 
MEDIAN ESTIMATED 
VALUE 
IL-6 (pg/ml) 1040 1180 
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TABLE-30 
MORTALITY PREDICTION IN PATIENTS WITH COMMUNITY 
ACQUIRED SEPSIS WITH CRP CONCENTRATION 
 
TEST VARIABLE MEAN ESTIMATED VALUE 
MEDIAN ESTIMATED 
VALUE 
CRP(mg/l) 350 384 
 
CHART 14 
 
 Table 29, 30 depicts that the mortality in patients with community acquired 
BSI could be predicted with median estimated value of IL-6 conc. of 1180pg/ml 
and CRP conc. of 384mg/l statistically. 
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TABLE-31 
MOLECULAR IDENTIFICATION OF ANTIMICROBIAL RESISTANT 
GENES- BY PCR 
 
RESISTANT 
STRAINS PRIMERS RESULT 
ESBL PRODUCERS(3) blaTEM POSITIVE 
ESBL PRODUCERS(3) blaCTX-M POSITIVE 
MRSA STRAIN(1) mecA POSITIVE 
 
  
Discussion 
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DISCUSSION 
 
 Bloodstream infections are an important cause of mortality and also 
morbidity related to sepsis. This study was focussed to know the burden of 
community acquired bloodstream infections in our settings and also to find a 
better diagnostic marker in detection of infections and sepsis.  
 
 During the study period of 1 year from March 2017- February 2018, blood 
culture was done in 150 patients with clinical suspicion of sepsis within 48hrs of 
hospital admission. Out of which, community acquired bloodstream infection was 
detected in 12 patients (8%), in this study. Tufail Soomro et al53 (2016) concluded 
in their study that the frequency and incidence of community acquired 
bloodstream infection was 7.6%. B Sigauque et al 54 in their study had identified 
community acquired bloodstream infection in 8% of patients on hospital 
admission correlating well with our study. In a cohort study of 3901 patients with 
community acquired sepsis conducted by Nathan I. Shapiro et al, 55 the incidence 
of bloodstream infection at hospital admission was 8.2%.   
 
 In the present study, patients in the age group between 51-60yrs were 
predominantly affected with community acquired bloodstream infection (50%) 
and males were the predominantly affected groups (75%) than females (25%). In 
the study conducted by J. Goncalves- Pereira et al56 and in the study of Ssali FN et 
al 57 males were predominantly affected with community acquired bloodstream 
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infection. In Tufail Soomro et al53 study, females were the predominantly affected 
groups (61.5%).  
 
 In the present study, out of 12 patients with community acquired 
bloodstream infection, the frequency and distribution of pathogens were 58% 
Gram positive organisms and 42% Gram negative organisms. 
 
 Among the Gram positive organisms, 85.7% were methicillin sensitive 
Staphylococcus aureus (MSSA) and 14.3% were methicillin resistant 
Staphylococcus aureus (MRSA). Hence, among the Gram positive organisms, 
14.3% were found to be resistant pathogens. In the study conducted by J. 
Goncalves- Pereira et al56 also the predominant Gram positive organism isolated 
were methicillin sensitive Staphylococcus aureus and the predominant Gram 
negative organisms identified were Escherichia coli. In a study done by Klevens R 
M et al, 58 incidence of community associated methicillin resistant Staphylococcus 
aureus infection was found to be 14%.   
 
 In this study, among the Gram negative organisms, Escherichia coli 
contributed 60%, Pseudomonas aeruginosa and Acinetobacter baumannii each 
contributed 20% respectively. The study by Parkins MD et al, 59 also showed that 
the incidence of community acquired bloodstream infection cases caused by 
Pseudomonas aeruginosa were 21%, well correlates with our study. Also, in a 
study of Chung-Ting Chen et al60 (2017), Acinetobacter baumannii isolates were 
identified as the causatives of community acquired bloodstream infections and for 
these isolates, respiratory tract was the primary source involved which matches 
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with the present study where the Acinetobacter baumannii isolate identified was 
acquired from respiratory tract as primary source of infection.  Among the Gram 
negative organisms isolated, 60% were found to be resistant pathogens especially, 
extended spectrum beta-lactamase (ESBL) producers among Escherichia coli 
organisms. Quan J et al, 61 (2017) study revealed 56% of ESBL producing E.coli 
isolates were identified in community acquired bloodstream infections. 
 
 In the present study, among Gram positive organisms isolated, methicillin 
sensitive Staphylococcus aureus were highly sensitive to Penicillin(100%), 
Erythromycin(100%), Tetracycline(100%), Linezolid(100%), Vancomycin(100%) 
and were resistant to Cotrimoxazole(66.7%) and Ciprofloxacin(50%).Methicillin 
resistant Staphylococcus aureus was highly sensitive to Ciprofloxacin(100%), 
Erythromycin(100%), Linezolid(100%), Vancomycin(100%) and were highly 
resistant to Penicillin(100%), Cotrimoxazole(100%) and Tetracycline(100%). 
 
 Among the Gram negative organisms isolated, Escherichia coli isolates 
were highly sensitive to Amikacin(100%), Tetracycline(100%)  and were found 
highly resistant to Ciprofloxacin, Cotrimoxazole, Ampicillin, Cefotaxime each 
100% respectively and Gentamicin(66.7%).Pseudomonas aeruginosa  was highly 
sensitive to Amikacin(100%), Gentamicin(100%), Ciprofloxacin(100%), 
Piperacillin-Tazobactum(100%), Imipenem(100%) and were highly resistant to 
Ceftazidime(100%). Acinetobacter baumanii isolate was highly sensitive to 
Tetracycline (100%), Piperacillin-Tazobactum (100%), Imipenem (100%) and 
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were highly resistant to Amikacin (100%), Gentamicin (100%), Ciprofloxacin 
(100%), Cotrimoxazole (100%) and Ceftazidime (100%). 
 
 In the present study, Gram positive organisms obtained were 
predominantly from patients from Intensive Care Units (42.9%) and (28.6%) were 
from patients from Medical wards. Gram negative organisms obtained were 
predominantly from Medical wards (80%) and remaining from Intensive Care 
Units (20%). 
 
 In this study, the co-morbidities and risk factors associated in patients with 
community acquired bloodstream infections were Diabetes mellitus (75%), 
Hypertension (33.3%), smoking (25%), anaemia (58.3%), and alcoholism 
(33.3%). Of which, the predominant risk factors were Diabetes mellitus (75%) 
and anaemia (58.3%) in this study. The study by Chung- Ting Chen et al60 also 
showed that diabetes mellitus was the predominant risk factor associated with 
community acquired bloodstream infection. 
 
 In our study, the primary system involved in community acquired 
bloodstream infection patients were respiratory system (66.7%) followed by 
intraabdominal infections (16.7%), renal involvement (8.3%), skin and soft tissue 
infections (8.3%).  Respiratory tract infection (66.7%) was the predominant 
source of infection for bacteraemia in the present study. Similar findings were 
observed in the study of J. Goncalves- Pereira et al56 ( 2013), with respiratory 
system being the predominant primary source involved (60.6%). In Pedersen G et 
al1 study, the commonest source of infection was the urinary tract (29%).  
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 Molecular characterization of resistant isolates were done  using 
polymerase chain  reaction (PCR) which showed the presence of  bla TEM and 
bla CTX-M genes, that confirmed ESBL producers among the Escherichia coli 
isolates and similarly, the presence of mecA gene confirmed methicillin resistant 
Staphylococcus aureus. Luzzaro F et al,62 in his study found that the most 
prevalent ESBL producing Gram negative organism was found to be Escherichia 
coli and TEM- type ESBLs were found to be the most prevalent enzymes 
(45.4%).According to the study by Rossolini GM et al,63 the CTX-M-type ESBLs 
had undergone a rapid and global spread in Enterobacteriaceae recently. In Mario 
Tumbarello et al64 study, the predominantly isolated ESBL genes were bla CTX-
M (36.5%) followed by bla TEM gene (28.7%).Nagat Sobhy et al65 study 
emphasized that the identification of the mecA gene is the most reliable method 
for detecting the MRSA isolate.   
 
 Biomarkers of sepsis are very useful both in diagnosis and prognosis, also 
in assessing the severity of infection. In the present study, inflammatory markers, 
C-reactive protein (CRP) and Interleukin-6(IL-6) were tested and correlated with 
blood culture positivity (Statistically significant with a p value of 0.01).  
 
 All the serum samples which were collected from patients with evidence of 
sepsis were tested for C-reactive protein concentration using latex slide 
agglutination method. The concentration of CRP was found elevated in patients 
with positive blood culture (CRP conc. ranged between 190-400mg/l). 62 samples 
(52.5%) showed the CRP concentration range between 11-70mg/l, 30 samples 
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(25.4%) were in the range between 71-130mg/l, 14 samples (11.9%) were in the 
concentration range between 131-190mg/l and remaining 32 samples (21.3%) 
were in the range between 6-10mg/l. 
 
 Serum samples were tested for CRP, on the day of sample collection itself; 
hence results were obtained prior to blood culture report. 12 samples (10.2%) 
denoted a higher CRP concentration range between 190-400mg/l and these 
samples also showed blood culture positivity, which indicated that detection of 
CRP is useful as an early biomarker of sepsis.  
 
 CRP concentration range among Gram positive organisms were found 
between 190-200mg/l and among Gram negative organisms, the CRP 
concentration range was found between 190-400mg/l. There was no significant 
difference in CRP concentration range between Gram positive and Gram negative 
organisms were found. Among the resistant strains, CRP concentration of MRSA 
isolate was 192mg/l and the concentration range among ESBL producers were in 
the range between 300-400mg/l. 
 
 Also the same serum samples were tested for interleukin-6 levels by using 
sandwich ELISA method and all the culture positive cases showed higher 
concentration of interleukin -6 i.e. above 200pg/ml. 58 samples (59.2%) belonged 
to the concentration range between 70-120pg/ml, 28 samples (28.6%) were in the 
range between 12-60pg/ml and 52 samples (34.7%) showed the concentration 
range between 3-11pg/ml. 
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 Interleukin-6 concentration levels among Gram positive organisms ranged 
between 300-900pg/ml and regarding Gram negative organisms, among 
Escherichia coli isolates, the concentration range was between 900-1200pg/ml.  
The concentration level of IL-6 in Pseudomonas aeruginosa isolate detected was 
found to be (1000-1200pg/ml) and for the Acinetobacter baumannii isolate 
identified, the IL-6 concentration level was found to be (600-
800pg/ml).According to Ryuzoabe et al 66 (2010) study, the IL-6 levels and the 
CRP concentrations were found to be significantly elevated in sepsis due to Gram 
negative infections when compared to Gram positive infections suggesting a 
different immunomodulatory response. Among the resistant strains isolated, the 
interleukin-6 concentration for MRSA strain was found to be 826pg/ml and 
among the ESBL producers isolated, the concentration range was found between 
900-1200pg/ml. 
 
 In this present study, out of 12 patients detected with community acquired 
bloodstream infections, 9(75%) recovered and 3(25%) expired. In the study by 
Sigauque B et al, community-acquired bacteraemia associated mortality 
accounted for 21% of hospital deaths. In the study by Valles J et al, 67 mortality 
rate in community- acquired bacteraemia was found to be 41.5%.Hence, this 
showed that the mortality rate in community acquired bloodstream infection/ 
sepsis could range between 21-42%.  Among the recovered group of patients, the 
CRP concentration range was between 190-200mg/l and the interleukin-6 levels in 
these patients were in the range between 400-800pg/ml. Among 3 patients who 
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expired, their CRP concentration was in the range between 300-400mg/l and the 
IL-6 concentration ranges between 900-1200pg/ml.  
 
 Also in this study, out of 138 patients, who fulfilled the SIRS criteria 
clinically, but were culture negative, 136 patients (98.6%) got recovered and 2 
patients (1.4%) expired. Among 136 patients who recovered, the CRP 
concentration range was found between 6-50mg/l and the interleukin-6 level was 
in the range between 3-60pg/ml. Among the 2 patients who expired, their CRP 
concentration range was between 131-190mg/l and the interleukin-6 concentration 
range was between 70-120pg/ml.  
 
 In the present study, CRP total positives were found to be 118(78.7%) and 
the total negatives were found to be 32(21.3%) with CRP cut- off being 6mg/l. IL-
6 levels total positives were found to be 103(68.7%) and the total negatives were 
found to be 47(31.3%) with IL-6 cut- off value considered as 10pg/ml. According 
to Martin Hoenigl et al68 study, the sensitivity of IL-6 with the recommended cut-
off of 10pg/ml was more promising (sensitivity 99.6%). In another study by 
Hassan Boskabadi et al, 69 serum IL-6 at a cut-off value of 10pg/ml had a higher 
sensitivity 92.5% and positive predictive value of 97%. Hence, this cut-off value 
for IL-6 been chosen for this present study. 
 
 In this study, IL-6 was found to be both sensitive and specific than CRP as 
early sepsis marker statistically. Sensitivity of IL-6 was found to be 83% and 
specificity was 84%(95%confidence interval for sensitivity- lower limit 75% and 
the upper limit 89% and for specificity- lower limit 66% and the upper limit 
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94%)in CRP positive suspected sepsis cases. In the study by Noor MK et al,70 IL-
6 level was raised with high sensitivity 77% and specificity 74% in CRP positive 
suspected sepsis cases and hence, concluded in this study that, IL-6 is a very early 
marker of sepsis compared to CRP.  
 
 In this study, the sensitivity and specificity was confirmed by calculating 
positive predictive value of 95% and a negative predictive value of 57% (95% 
confidence interval for positive predictive value- lower limit 88% and the upper 
limit 98% and for negative predictive value- lower limit 42% and the upper limit 
71%). 
 
 Further an ROC curve was plotted and obtained which showed the area 
under the curve was greater for IL-6(67%) than CRP (61%). This proved that IL-6 
was found as a better early sepsis marker than CRP.  
 
 Also, statistically the median estimated IL-6 level by which the mortality in 
patients with community acquired sepsis could be predicted was found to be 
1180pg/ml according to this study and the mean estimated IL-6 level was found to 
be 1040pg/ml. Pierre Damas et al71 study found that the mortality rate increased 
significantly in the patients with IL-6 serum levels above 1000pg/ml which 
correlates well with the present study. Similarly, the median estimated CRP 
concentration by which the mortality in patients with community acquired sepsis 
could be predicted was found to be 384mg/l and the mean estimated CRP 
concentration was found to be 350mg/l. Shungo Yamamoto et al72 study analysed 
that serum CRP levels >= 150mg/l was an independent predictor of death.    
Summary 
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SUMMARY 
 
 The study was done during a period of 1year from March 2017- February 
2018 at Institute of Microbiology in collaboration with the Institute of Internal 
Medicine and Surgery. The study group included 150 patients in the age group > 
18yrs with clinical suspicion of sepsis admitted within 48hrs in Medical, surgical 
wards and Intensive Care Units at Rajiv Gandhi Government General Hospital.  
 
 The presenting symptoms in the present study were fever, cough, 
dyspnoea,    abdominal pain, vomiting, dysuria, ulcerative skin lesions, swelling 
legs, malena/bleeding disorders, altered sensorium, seizures.  
 
 Blood culture was done in these 150 patients prior to antibiotic 
administration, of which community acquired bloodstream infection was detected 
in 12patients (8%). 
 
 Majority of patients 6(50%) with community acquired bloodstream 
infection belonged to the age group between 51-60 yrs and males were 
predominantly affected 9(75%) than females 3(25%). 
 
 The organisms isolated were 58% Gram positive organisms and 42% Gram 
negative organisms. 
 
 Majority of clinical isolates were from Medical unit (both general wards 
and Intensive care unit). Gram positive isolates obtained were predominantly from 
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Intensive Care Unit (42.9%) and Gram negative isolates obtained were 
predominantly from general medical wards (80%). 
 
 Among the Gram positive organisms- 85.7% were Methicillin sensitive 
Staphylococcus aureus (MSSA) and 14.3% were Methicillin resistant 
Staphylococcus aureus (MRSA). 
 
 Among the Gram negative organisms, 60% Escherichia coli, 20% 
Acinetobacter baumannii and 20% Pseudomonas aeruginosa were isolated. 
 
 Antimicrobial susceptibility testing was done for these organisms which 
detected 60% ESBL producing Escherichia coli isolates using both screening test 
and phenotypic confirmatory test as per CLSI guidelines. Also, Staphylococcus 
aureus isolates were tested for Methicillin resistance by disk diffusion method 
using cefoxitin (30µg) disk and 14.3% Methicillin resistant Staphylococcus 
aureus isolate was identified and then confirmed by PCR, by detecting mecA 
gene. Gram positive organisms were found highly sensitive to Erythromycin, 
Vancomycin, Linezolid each 100% respectively and the Gram negative organisms 
were found highly sensitive to Amikacin, Tetracycline each 100% respectively. 
 
 Vancomycin sensitivity in Gram positive organisms tested using 
Vancomycin screen agar and E –strip test found to be sensitive to Vancomycin. 
 
 Antimicrobial resistant genes for the resistant isolates were detected using 
PCR. bla TEM and bla CTX-M genes were found positive among ESBL 
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producing Escherichia coli isolates and mecA gene was found to be positive in 
Methicillin resistant Staphylococcus aureus isolate. 
 
 Diabetes mellitus (75%) and anaemia (58.3%) were found to be 
predominant risk factors associated in patients with community acquired 
bloodstream infection in this study. 
 
 Respiratory system was the predominant primary system involved (66.7%) 
in patients with community acquired bloodstream infections according to this 
study. 
 
 Inflammatory markers CRP and IL-6 concentrations were tested using 
latex slide agglutination method and sandwich ELISA method respectively and 
correlated with blood culture positivity. Where CRP and IL-6 levels were both 
found to be positive and were significantly elevated in blood culture positive 
samples (CRP concentration ranged between 190-400mg/l and IL-6 concentration 
was >= 200pg/ml). 
 
 IL-6 was found to be both sensitive and specific than CRP as early sepsis 
marker statistically with sensitivity 83%(95% CI- 75%-89%), specificity 
84%(95% CI-66%-94%), positive predictive value 95%(95% CI-88%-98%) and 
the negative predictive value 57%(95% CI-42%-71%) in CRP positive suspected 
sepsis cases. Also ROC curve plotted showed, area under the curve for IL-6 
(67%) was more than CRP (61%). This proved, IL-6 as a better early sepsis 
marker than CRP as per this study. 
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 The clinical outcome of the patients with community acquired bloodstream 
infection, (75%) recovered and (25%) expired. Among the patients who expired, 
CRP and IL-6 levels were significantly raised (CRP concentration ranged between 
300-400mg/l, IL-6 concentration ranged between 900-1200pg/ml) than the 
recovered group (CRP concentration ranged between 190-200mg/l, IL-6 
concentration ranged between 400-800pg/ml). 
 
 In this study, statistically the median estimated IL-6 level by which the 
mortality in patients with community acquired sepsis could be predicted was 
found to be 1180pg/ml and the median estimated CRP concentration was found to 
be 384mg/l.  
 
 Correlation of inflammatory markers (CRP and IL-6) in this study 
was statistically significant with a p value of 0.01. 
   
  
Conclusion 
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CONCLUSION 
 
 Community acquired bloodstream infections are rising as a major health 
problem in upcoming years due to the emergence of antimicrobial resistant 
organisms which were once confined to hospital settings are now a potential 
threat in the community settings as well like ESBL producing 
Enterobacteriaceae, MRSA etc... 
 Hence, these antimicrobial resistant strains should be promptly identified 
through proper surveillance. Molecular characterization of resistant pathogens 
helps in tracking the spread of antimicrobial resistance in the community. 
  Also, appropriate antibiotic policy and preventive strategies has to be framed 
to curtail the spread of these antimicrobial resistant strains in the community 
settings. 
 Inflammatory markers such as CRP, IL-6 have a major role in early sepsis 
detection. Of which, IL-6 is found to a better early marker of sepsis than CRP 
which reveals positivity within 24hrs of onset of sepsis than the conventional 
blood cultures. But still, blood culture remains the confirmatory and gold 
standard method in the detection of sepsis.   
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Annexures 
APPENDIX 
                                           ABBREVIATIONS 
BHI broth - Brain heart infusion broth 
MSSA - Methicillin sensitive Staphylococcus aureus 
MRSA - Methicillin resistant Staphylococcus aureus 
ESBL - Extended spectrum beta-lactamase 
SIRS  - Systemic inflammatory response syndrome 
CRP  - C-reactive protein 
IL-6  - Interleukin-6 
PCR  - Polymerase chain reaction 
CLSI  - Clinical and Laboratory Standards Institute 
SD  - standard deviation 
ROC curve - Receiver Operating Characteristic Curve  
INR  - International Normalized Ratio 
  
ANNEXURE – I 
 
ANNEXURE – II 
 
PROFORMA 
 
 Name: 
 Age/gender: 
 IP no:        
  Date of admission: 
 Presenting complaints: 
 Past history: 
 Personal history: 
 Treatment history: 
 Travel history: 
 Investigations: 
 
 
  
ANNEXURE - III 
CONSENT FORM 
STUDY TITLE:  
 A STUDY ON COMMUNITY ACQUIRED BLOODSTREAM 
INFECTIONS, MOLECULAR CHARACTERIZATION OF RESISTANT 
PATHOGENS AND CORRELATION WITH INFLAMMATORY MARKERS IN 
A TERTIARY CARE HOSPITAL. 
 
 
 I…………………………………………, hereby give consent to 
participate in the study conducted  by Dr.A.PRIYADHARSHINI, Post graduate 
at Institute of Microbiology, Madras Medical College, Chennai and to use my 
personal clinical data and the result of investigations for the purpose of analysis 
and to study the nature of the disease, I also give consent to give my clinical 
Sample (blood) for further investigations. I also learn that there is no additional 
risk in this study. I also give my consent for my investigator to publish the data in 
any forum or journal. 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
Patient Name & Address: 
 
Signature of the investigator: 
 
Signature of guide: 
  
ANNEXURE - IV 
 
INFORMATION SHEET 
 
STUDY TITLE:  
 A STUDY ON COMMUNITY ACQUIRED BLOODSTREAM 
INFECTIONS, MOLECULAR CHARACTERIZATION OF RESISTANT 
PATHOGENS AND CORRELATION WITH INFLAMMATORY MARKERS IN 
A TERTIARY CARE HOSPITAL.  
 
 
INVESTIGATOR  : Dr.A.PRIYADHARSHINI, 
                                    Post Graduate, 
    Institute of Microbiology, 
  Madras Medical College, 
  Chennai - 600003 
 
GUIDE   : Dr. C.P.RAMANI, M.D., 
                                     Professor of Microbiology, 
                                     Institute of Microbiology, 
                                     Madras Medical College, 
                                     Chennai - 600003 
 
 In this study, I am going to collect blood samples from patients with informed 
consent who have been hospitalized within 48 hours with sepsis and process them to 
identify the causative agents of community acquired bloodstream infections.150 patients 
will be included in this study only after getting informed consent. Also, in this study the 
multidrug resistant pathogens will be characterized by phenotypic and genotypic 
methods. Early biomarkers of sepsis such as C-reactive protein, Interleukin-6 determined 
and correlated with blood culture positivity. 
 
 This study is entirely voluntary and patient can withdraw any time from this 
study. Extra cost will not be incurred to the patients in this study. Any doubt regarding 
this study will be clarified. Results of this study will be published. In case of any doubt 
please contact, Dr.A.PRIYADHARSHINI, CELL: 8903792132. 
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dehydration+
P/A-epigastric tenderness+
L hemiparesis
11.5 14700
72%19%1%0%1%
22 160,000 85.7 27.3 32.9
scrub typhus 
Igm-positive
NG 48 96 recovered
2 parthiban 19 m 113/82293 7.3.17
fever, cough, joint 
pains
febrile,BP-90/60mmHg,PR-
102/mt,CVS/RS-NAD
14.5 4900  78%22%0%1%0% 14 138,000 85.2 27.3 32 - NG 12 72 recovered
3 sampath 51 m 212/82316 8.3.17
fever,cough,dyspn
oea,
myalgia 
febrile,BP-80/60mmHg,
dyspnoeic,tachypnoeic,
PR-108/mt,RR-26/mt,
eschar/ulcer-R scrotum
15.8 13900
76%21%1%1%0%
16 80,000 88.2 31 35.1
CT chest-L 
pleural
effusion, IgM 
Dengue 
positive
NG 48 32 recovered
4 Balaji 57 m 113/82327 9.3.17
fever,vomiting,mya
lgia
febrile,BP-100/70mmHg,
dehydration+,PR-102/mt,
P/A-splenomegaly+
10.6 3800 70%18%0%0%0% 12 202,000 79.5 26.5 32.1
P.S-P.vivax
USG abd-
splenomegaly
NG 6 3.13 recovered
5 Baskar 23 m 113/82352 9.3.17 fever,myalgia
febrile,BP-90/60mmHg,
PR-98/mt,dehydration+
12.2 5000 74%32%0%1%0% 18 75000 86.2 28.1 33.1
IgM Dengue 
positive
NG 12 54 recovered
6 selvamani 21 m 113/82370 10.3.17 fever,myalgia
febrile,PR-108/mt,BP-90/70
mmHg,dehydration+, 11.9 3400 68%31%1%0%0% 10 68,000 82.4 32.1 34.2
IgM Dengue 
positive
NG 12 48 recovered
7 Rajeswari 32 f 212/82245 13.3.17
fever,pain 
abdomen,
vomiting,cough,dys
pnoea
febrile,PR-106/mt,
BP-80/60mmHg,rashes,abd.
Distension,dyspnoeic,
tachypnoeic,RR-28/mt,
RS-R lung base reduced 
breath sounds
11.2 15100 80%29%1%1%0% 18 59000 85.4 28.9 33.9
IgM Dengue 
positive
USG abd-R 
pleural
effusion with 
mod. Ascitis
NG 24 32 recovered
8 Sarathy 20 m 125/82863 16.3.17
fever,vomiting,alte
red
sensorium
febrile,BP-100/60mmHg,
drowsiness,dehydration+
PR-102/mt
12.1 13000 78%21%0%0%0% 14 166,000 86.2 28.7 33.3 hyponatremia NG 6 4.2 recovered
9 Muniyandi 21 m 212/83372 17.3.17
fever,vomiting,pain
abdomen,bleeding 
gums
febrile,BP-80/60mmHg,
PR-96/mt,dehydration+
10.2 4300 65%24%0%0%0% 12 60,000 78.1 27.6 32.1
IgM Dengue 
positive
NG 12 46 recovered
10 Roja 35 f 123/81858 19.3.17 fever,myalgia
febrile,dehydration,
PR-104/mt,BP-100/70mmHg
12.3 8600 72%22%1%0%0% 16 120,000 86.5 28.2 32.6 PS-P.vivax NG 6 6.25 recovered
11 Syed 23 m 145/83036 24.3.17
fever,vomiting,mya
lgia
febrile,BP-90/60mmHg,
dehydration+
12 9600 76%28%0%1%0% 12 96000 86.2 28.2 32.6
IgM Dengue 
positive
NG 96 24 recovered
12 Yasodha 35 f 121/83485 10.4.17
fever,vomiting,pain
abdomen 
febrile,BP-100/70mmHg,
PR-102/mt,dehydration+
11.3 8400 74%22%0%0%1% 16 222,000 92.8 31.5 33.9 - NG 6 6.25 recovered
13 Prema 55 f 121/83553 14.4.17
fever,headache,
myalgia
febrile,BP-90/60mmHg,
PR-104/mt
12 7900 78%29%1%0%0% 18 169,000 83.4 28.4 34 - NG 6 5.6 recovered
14 Ellammal 75 f 124/2161 16.4.17
fever,dyspnoea,alt
ered
sensorium,vomitin
g
febrile,drowsy,PR-110/mt
BP-80/60mmHg,b/l basal lung
crepts,dehydration+
11.2 14100 82%28%0%1%1% 28 194,000 88.2 26.5 30.1
urine acetone-
positive
urineRE-albumin 
2+
NG 24 76 recovered
15 Usman 21 m 212/3000 18.4.17
fever,vomiting,sync
ope
febrile,PR-106/mt,
BP-100/70mmHg,dehydration
13.8 5300 72%24%0%1%0% 14 150,000 81.6 29.6 36.2 - NG 12 3 recovered
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16 Hemavathy 68 f 122/2875 22.4.17
fever,inc.freq.of 
micturition,dyspno
ea,
altered sensorium
febrile,drowsy,PR-108/mt,
dehydration,spo2-88%,
BP-160/100mmHg
10.6 16500 80%28%0%1%0% 12 264,000 88.9 29.5 30.2
hyponatremia
MRI brain-
Periventricular 
white matter 
hypodensities
NG 12 6.25 recovered
17* Vasantha 61 f 212/3158 26.4.17
fever,vomiting,dys
pnoea
reduced urine 
output
febrile,dehydration,pallor+
PR-110/mt,BP-80/60mmHg,
b/l pedal edema,b/l basal
lung crepts,spo2-86%,
L foot ulcer-non healing
9.3 19600 86%34%1%1%0% 26 224,000 76.9 26.7 31.3
CXRay-b/l basal 
lung
infiltrates
Staphyloc
occus 
aureus
192 425 recovered
18 Lokesh 28 m 212/2970 27.4.17
fever,pain 
abdomen,
vomiting,dyspnoea,
reduced urine 
output
febrile,dyspnoeic,
BP-90/70mmHg,spo2-88%
b/l basal lung crepts
12.9 13200 76%26%0%1%0% 18 83000 80.3 28.8 34.1
CXRay-
b/lpleural 
effusion
CT chest-b/l 
pleural 
effusion with 
collapse
lung R>L,pl.fluid 
cytology
reactive 
effusion,dengue
IgM-positive
NG 48 50 recovered
19
Sathish
kumar
27 m 212/85242 30.4.17
fever,chills&rigors,
vomiting,cough,ma
lena
passage of dark 
coloured
urine
febrile,dehydrated,L eye
congestion,PR-102/mt
BP-100/60mmHg,b/lbasal
lung crepts,epigastric
tenderness
10.1 15100 82%30%0%0%1% 16 19000 72.3 25.1 32.3
CXRay-b/l lung 
infiltrates
with 
consolidation,
dengue IgM -
positive
NG 24 84 recovered
20* Puratchipathi 67 m 113/3855 10.6.17
fever,dyspnoea,vo
miting
cough with 
expectoration
reduced urine 
output
febrile,dyspnoeic,pallor+
PR-112/mt,BP-80/60mmHg,
spo2-80%RA,tachypnoeic,
RR-32/mt,b/l lung extensive
 crepts,abd.distension
8.6 22600 88%34%1%0%0% 25 110,000 77.1 23.3 30.3
USG abd-gross 
ascitis
CT chest-R 
upper lobe
consolidation,L 
upper 
lobe fibrosis
Pseudomo
nas 
aeruginos
a
384 1180 expired
21
kamala
kannan
28 m 124/3840 12.6.17
fever,vomiting,hea
dache
seizure1episode
febrile,postictal drowsy
 confusional state,
BP-100/70mmHg
12.6 13200 72%22%0%0%1% 18 232,000 88.8 29.2 32.9 - NG 6 5.8 recovered
22 Mohanraj 37 m 124/85816 15.6.17
fever,headache,sei
zures1
episode,involuntar
y
micturition after 
fits
febrile,postictal phase,
PR-104/mt,dehydration+
tongue bite+
RS-added sounds+
12.1 12200 66%24%0%1%0% 12 115,000 85.9 27.9 32.4 - NG 6 3 recovered
23 Gurunadhan 65 m 124/3700 18.6.17
fever,pain 
abdomen,
inc.frequency of 
micturition
febrile,BP-90/60mmHg,
dehydrated,PR-102/mt,
suprapubic tenderness
12.6 15400 66%21%0%2%1% 14 232,000 89.2 32.4 36.1
urine RE-pus 
cells-10-15
urine c/s-
growth+
NG 12 3.13 recovered
24 Sadaiyappan 35 m 223/3039 23.6.17
fever,pain 
abdomen,
vomiting
febrile,PR-108/mtBP-100/60
mmHg,dehydrated
abd.-epigastric tenderness+
16.2 13600 76%25%1%0%1% 22 234,000 92.9 33.6 36.9
sr.amylase-
372IU/L
USGabd-
pancreas 
obscured by 
bowel 
shadow,otherwi
se
nothing 
significant
NG 12 54 recovered
seizure disorder-
5yrs 
on irregular
treatment
nil
HT-15yrs,old 
CVA
DM-4yrs,HT-
4yrs on
treatment
DM,HT-12yrs,
hypothyroidism-
5yrs
nil
nil
chronic 
alcoholic
seizure disorder-
8yrs
on irregular 
treatment
chronic 
alcoholic,
25* Poomani 55 f 121/84888 28.6.17
fever,swelling&pai
n L leg
dyspnoea,abdomin
al
distension
febrile,drowsy,PR-110/mt,
BP-80/60mmHg,spo2-92%
L lung basal crepts,abd.
Distension,L leg-edema+,
warmth,tenderness,blebs+
10.2 21600 92%36%0%1%0% 26 262,000 77.2 28.6 32.1
CXRay-L minimal 
pleural
effusion,USGab
d-
minimal 
ascitis,fatty liver
Staphyloc
occus 
aureus
192 568 recovered
26
Santhosh 
kumar
22 m 134/85393 29.6.17
fever,vomiting,mya
lgia,
seizures 1 episode
febrile,drowsy,PR-102/mt,
BP-100/70mmHg 13.2 13200 74%24%0%0%1% 22 162,000 87.3 30.9 35.4 - NG 6 3.2 recovered
27* Sakthivel 52 m 213/87000 30.6.17
fever,swelling in 
perianal
region with severe 
pain
febrile,BP-80/60mmHg,
PR-114/mt,swelling perianal
region burst open to 
ulcerative lesion with
mucopurulent discharge,
L inguinal lymphadenopathy,
dehydrated
13 18600 86%36%0%1%0% 24 126,000 87.6 35.9 36.2 -
Staphyloc
occus 
aureus
192 482 recovered
28 Deepika 21 f 123/2278 30.6.17
fever,dyspnoea,red
uced
urine output
febrile,PR-104/mt,
BP-90/60mmHg,spo2-90%,
L lung basal crepts,pallor+
8.5 13500 78%26%0%0%1% 20 24,000 76.2 26.2 32.6
CXRay-haziness 
L lower
lobe,USG abd-
minimal 
L pleural 
effusion,dengue
IgM-positive
NG 24 86 recovered
29*
Yulandha 
mary
72 f 241/85904 2.7.17
fever,dyspnoea,red
uced
urine 
output,altered 
sensorium
febrile,not oriented,
unconscious,pallor+,
PR-120/mt,BP-80/60mmHg,
spo2-85%,b/l lung basal
crepts
8.4 21200 89%34%0%1%1% 26 262,000 74.2 25.4 31.2
CT chest- L lung 
consolidation,CT 
brain-
multiple 
hypodense 
lesion both 
frontal/
parietal region,
USGabd-b/l gr-1 
MRD
Staphyloc
occus 
aureus
192 620 recovered
30 Selvam 54 m 134/87636 3.7.17
fever,vomiting,alte
red
sensorium
febrile,unconscious,not 
oriented,BP-100/60mmHg,
tachypnoeic,spo2-89%
L lung basal crepts
10.2 12600 74%36%5%0%1% 18 269,000 77.6 29.3 32.7
Hyponatremia,C
T brain-
L -GC 
hypodensity
NG 12 9.8 recovered
31 Selva kumar 42 m 134/87686 3.7.17
fever,pain 
abd.,reduced
urine output,abd.
Distension,malena,
hemetemesis
chronic 
alcoholic
febrile,hypotension,pallor+
dehydration,abd.
Distension,BP-90/60mmHg
10.8 15,600 71%28%3%0%0% 16 80,000 74.6 29.7 32.3
USGabd-ascitis,
hepatomegaly,d
engue IgM-
positive
NG 48 84 recovered
32 Dharani 34 f 123/84327 5.7.17
fever,pain 
abdomen,
mild 
dyspnoea,vomiting
febrile,PR-102/mt,
BP-100/70mmHg,dehydration
P/A-epigastric tenderness+
10.9 6800 76%21%0%1%0% 14 228,000 86.7 27.8 32.1 - NG 12 3 recovered
33 Thangavel 60 m 134/87655 5.7.17
fever,reduced 
urine 
output,dysuria
febrile,dehydrated,pallor+
suprapubic tenderness+
8.5 12200 72%26%0%1%1% 16 168,000 77.8 26.2 32.3
urine-pus cells-8-
10
urine c/s-
growth+
CT abd- L-HUN
NG 24 4.5 recovered
DM-5yrs on 
treatment
DM-5yrs,HT-
5yrs,
seizure disorder-
4yrs
nil
DM-12yrs,HT-
11YRS
on treatment
nil
DM-1yr on 
treatment
DM-3yrs on 
treatment
seizure disorder-
3yrs
on irregular 
treatment
34 Parvathy 70 f 121/87413 7.7.17
fever,vomiting,bur
ning
micturition
febrile,dehydrated,pallor+
P/A-diffuse tenderness+
9.6 13800 74%28%1%1%0% 14 268,000 78.5 25 31.7
USGabd-
minimal free
fluid in 
abdomen
urine 
albumin+++
urine c/s-
growth+
NG 12 76 recovered
35 Desigamani 41 m 134/2115 7.7.17
fever with 
chills,myalgia
febrile,BP-90/60mmHg,
dehydration,
P/A-mild hepatomegaly+
13.5 11800 70%25%0%1%0% 16 80,000 83.4 28.4 34
USGabd-mild 
hepatomegaly,
dengue IgM-
positive
NG 24 94 recovered
36 Elumalai 55 m 113/45662 9.7.17
fever,vomiting,cou
gh,
dyspnoea
febrile,dyspnoeic,RR-26/mt,
BP-100/60mmHg,PR-104/mt,
L lung basal crepts
11.2 10900 76%26%0%1%0% 22 122,000 89 28.7 32.1
sputum c/s-
growth+
CXRay-haziness 
L lung 
lower lobe
NG 12 86 recovered
37 Bharathi 70 m 121/89398 12.7.17
fever,swelling with 
pain with ulcer
 1st metatarsal 
region L 
foot,vomiting,dysp
noea
febrile,BP-100/70mmHg,
PR-102/mt,ulcerative lesion 
L foot near 1st metatarsal 
region with 
serosanguinous 
discharge
10.2 13800 74%28%0%1%1% 16 257,000 81.6 26.2 32.7 pus c/s-growth+ NG 12 78 recovered
38 Ramesh 35 m 113/86023 13.7.17
fever,myalgia,coug
h
febrile,dehydrated,
BP-100/70mmHg,PR-102/mt,
RS-b/l rhonchi+
13.2 11700 70%19%0%1%0% 18 215,000 83.7 29.3 35 - NG 6 5.4 recovered
39 Kabir 32 m 134/87646 15.7.17
fever,vomiting,pain 
abd.
Myalgia,malena
febrile,BP-90/70mmHg,
PR-106/mt,dehydration+,
P/A-epigastric tenderness+
hepatomegaly,splenomegaly+
10.6 13200 70%24%0%0%0% 16 90,000 71.4 25.2 31.1
USG abd-mild
hepatosplenom
egaly
UGIscopy-
gastritis,dengue 
IgM-
positive
NG 12 72 recovered
40 Sundaramoorthy 25 m 211/89604 16.7.17
fever,vomiting,
arthralgia,dyspnoe
a,pain
abdomen.
febrile,PR-102/mt,
BP-100/60mmHg,spo2-89%,
RS-reduced breath sounds
b/l lung base
11.6 12900 72%26%0%1%0% 16 48000 74.6 25.8 32.1
USGabd-b/l 
pleural 
effusion,GB wall 
edema,
ascitis,CXRay-b/l 
pleural
effusion,dengue 
IgM-
positive
NG 24 110 recovered
41
Kamala
80 f 122/90369 17.7.17
fever, vomiting, 
altered 
sensorium
febrile,drowsy,BP-170/100
mmHg,spo2-89% ,L lung basal 
crepts,dehydrated
10.2 14200 76%28%1%0%0% 20 198,000 78.6 26.8 32.8
CXRay-L pleural 
effusion
MRI brain- age 
related 
changes
NG 12 76 recovered
42 Rakesh 21 m 211/89652 19.7.17
fever,arthralgia,vo
miting
febrile,dehydration,
BP-90/60mmHg, L lung basal
crepts,spo2-88%,
RR-24/mt,
11.9 13800 74%26%0%1%0% 12 65000 82.1 27.2 32.2
USG abd- 
ascites,mild L 
pleural effusion,
CXRay-mild L 
pleural 
effusion,dengue 
IgM-
positive
NG 24 84 recovered
DM-5yrs, HT-
4yrs on 
irregular 
treatment
nil
DM-3yrs on 
treatment
nil
nil
nil
DM-7yrs,HT-
6yrs,BA-
8yrs on 
treatment
nil
chronic 
alcoholic
43 Prem kumar 65 m 241/89295 20.7.17
fever,pain 
abd,dysuria
myalgia
febrile,BP-100/60mmHg,
dehydration,suprapubic
tenderness
10.9 14900 76%24%0%0%0% 14 262,000 84.2 28.6 32.6
urine-puscells 8-
10,
urine c/s-
growth+
NG 12 12.8 recovered
44 Mani 60 m 241/43624 22.7.17
fever,altered 
sensoriun,
seizures-1 
episode,vomiting
postictal phase,febrile,
BP-100/70mmHg,dehydrated
11.1 13900 75%28%0%1%0% 12 265,000 85.1 29.2 33.1
CT brain-
heterodense
lesion in L 
temporoparietal
region with 
specks of 
calcification 
seen
NG 6 3 recovered
45* Egambaram 83 m 111/93435 25.7.17
fever,vomiting,pain 
abd,
dysuria
febrile,dehydrated,
BP-80/60mmHg,pallor+,
suprapubic tenderness+
10.1 20200 86%36%0%0%0% 22 298,000 80.1 27.9 33.6
urineRE-pus 
cells-plenty
urine albumin-
3+ 
urine c/s- 
growth+
E.coli(ESBL
)
192 856 recovered
46 Arumugam 56 m 111/96627 25.7.17
fever,cough,dyspn
oea,
vomiting,reduced 
urine
output
febrile,dyspnoeic,RR-26/mt
PR-104/mt, BP-100/60mmHg,
spo2-89%, L basal lung
crepts
11.2 13800 78%42%0%1%1% 22 166,000 81.2 31.2 32.6
CXRay-b/l lung 
infiltrates
NG 12 3.4 recovered
47 Rajendran 45 m 111/96556 26.7.17
fever,vomiting,mya
lgia,
pain abd
febrile,dehydrated,icteric
BP-100/70mmHg, mild 
hepatomegaly
11.4 12100 76%28%0%0%1% 12 262,000 84.2 27.4 34.2
USG abd- mild 
hepatomegaly,
elevated liver 
enzymes,
 lepto- positive 
2+
NG 24 78 recovered
48 Moorthy 48 m 124/95827 27.7.17
fever with 
chills,myalgia
febrile,dehydrated,
BP-90/70mmHg,
P/A-mild splenomegaly
12.2 12900 72%24%0%0%0% 14 256,000 82.2 29.2 33.7
USG abd- mild 
splenomegaly,
P.S-P.vivax
NG 6 3.2 recovered
49 Thulasiammal 60 f 121/86522 28.7.17
fever,vomiting,pain 
abd,
myalgia
febrile,dehydrated,
BP-90/60mmHg,PR-104/mt,
L lung basal crepts+,
P/A- mild hepatomegaly
10.9 13000 76%29%0%1%1% 16 80,000 79.1 26.8 31.1
USG abd-mild 
hepatomegaly 
with
ascitis,CXRay-L 
lung base
infiltrates+,deng
ue IgM-
Positive
NG 24 98 recovered
50 Murugan 56 m 225/106182 29.7.17
fever,myalgia,arthr
algia,
malena
febrile,dehydrated,
BP-70/? on admission then
BP-80/60mmHg after i.v fluids
rashes over trunk+ pallor+
9.6 13900 78%26%0%1%0% 12 87000 78 25.6 31.8
USG abd-GB 
wall edema,
dengue IgM-
Positive
NG 12 112 recovered
51 Vijayakumari 28 f 224/106435 29.7.17
fever,headache,vo
miting,
myalgia, arthralgia
febrile,BP-100/60mmHg,b/l 
ankle swelling,PR-102/mt 12.2 13800 72%24%0%0%0% 18 180,000 80.6 27.6 32.2
IgM 
Chikungunya-
positive
NG 24 74 recovered
52 Madhavan 48 m 225/106656 30.7.17
fever,vomiting,alte
red 
sensorium
febrile,drowsy,not oriented
BP-90/70mmHg,PR-104/mt
12.9 12700 71%27%0%1%0% 12 230,000 86.2 27.8 32.3 hyponatremia NG 6 3 recovered
53 Maragatham 23 f 224/106232 31.7.17
fever,vomiting,pain 
abd
dysuria
febrile, dehydrated,
suprapubic tenderness
11.6 13600 76%22%0%0%1% 14 179,000 84.3 28.2 33.6
urine RE-pus 
cells 10-12
urine c/s- 
growth+
NG 12 3.2 recovered
54 Nagammal 60 f 122/107092 31.7.17
fever with 
chills,myalgia,
vomiting,pain 
abdomen
febrile,dehydrated,
BP-90/60mmHg,PR-102/mt,
P/A-epigastric tenderness+
12.4 12200 71%23%0%0%0% 10 220,000 81.9 27.2 31.3 - NG 12 4.6 recovered
HT-4yrs ,CAD 
on 
treatment
DM 12yrs on 
treatment
chronic 
alcoholic,
seizure disorder 
on 
irregular 
treatment
DM-10yrs on 
treatment
nil
nil
PTB 2012-
discontd 
treatment
HT-6yrs on 
treatment
HT-5yrs on 
treatment
nil
hypothyroid on 
treatment
chronic 
alcoholic
55 Sheikvalli 40 f 122/107442 3.8.17
fever,vomiting,pain 
abd,
jaundice
febrile,dyspnoeic,
BP-90/70mmHg,icteric,mild
hepatomegaly
11.3 9800 78%26%0%0%0% 13 266,000 85.2 26.7 32.4
USG abd-mild 
hepatomegaly, 
elevated
liver enzymes
NG 12 5.2 recovered
56 Fathima Banu 44 f 122/108058 4.8.17
fever,cough,dyspn
oea
febrile,BP-100/70mmHg,L lung
basal crepts,PR-104/mt,
RR-20/mt,spo2-90%
12.1 14900 78%36%0%1%0% 16 143,000 83.2 27 32.8
CXRay-L lung 
basal 
infiltrates
NG 24 5.6 recovered
57 Khan 23 m 221/116305 5.8.17
fever,vomiting,mya
lgia
febrile,dehydrated,
BP-90/70mmHg
11.9 13400 76%29%0%0%0% 11 231,000 84.6 27.7 32.9 - NG 6 8.4 recovered
58 Chinnapappa 60 f 143/117203 12.8.17
fever,arthralgia,my
algia
febrile,dehydrated,joint 
swelling and tenderness,
BP-90/60mmHg
11.6 12900 73%28%0%1%0% 19 188,000 85.4 26.9 32.1
IgM 
chikungunya-
positive
NG 12 96 recovered
59 Habeesha 48 f 121/118256 13.8.17
fever with chills, 
cough,
dyspnoea, chest 
discomfort
febrile,dyspnoeic,
PR-98/mt,BP-90/70mmHg,
L basal crepts-lung,spo2-
88%,RR-24/mt
10.3 14100 82%39%0%1%1% 21 234,000 78.9 27.1 30.2
CXRay-infiltrates 
L lung
f/s/o chronic 
bronchitis
NG 24 78 recovered
60 Keerthika 35 f 121/107185 14.8.17
fever with chills 
&rigors,
myalgia,vomiting
febrile,dehydrated,pallor+
BP-100/70mmHg,
splenomegaly,
epigastric tenderness
9.1 12300 70%24%0%1%0% 12 190,000 76.8 25.2 31.9
USG abd-
splenomegaly,
P.S.-P.vivax
NG 6 10.2 recovered
61 Rose whilet 28 f 225/116286 16.8.17
fever with chills, 
myalgia,
vomiting, pain abd
febrile,dehydrated,
BP-100/60mmHg,PR-102/mt,
P/A-mild hepatomegaly
11.2 7800 71%20%0%0%1% 13 169,000 72.3 28.6 38.5
USG abd- mild 
hepatomegaly,
IgM scrub 
typhus-positive
NG 12 104 recovered
62 Vijayakumari 42 f 121/109623 17.8.17
fever,myalgia,coug
h,
dyspnoea
febrile,BP-90/60mmHg,
PR-106/mt,dyspnoea,
RR-26/mt,spo2-92%,
RS-b/l rhonchi+
10.8 13700 77%32%0%1%0% 20 216,000 77.2 25 31.9 - NG 6 10.1 recovered
63 Vasanthi 35 f 123/115960 19.8.17
fever with 
chills,pain 
abd,dysuria,
vomiting
febrile,dehydrated,
BP-80/60mmHg,suprapubic
tenderness+
11.7 15900 74%25%0%1%0% 12 146,000 86.2 29.5 33.6
urine pus cells-
10-15
urine c/s-
growth+
NG 12 9.2 recovered
64 Joynal 24 m 145/115675 19.8.17
fever,headache,1 
episode
fits,involuntary 
micturition,vomitin
g-
1 episode
febrile,postictal phase,
PR-108/mt,spo2-94%,mild
dyspnoea,RR-24/mt
12.6 11300 73%28%0%0%0% 15 245,000 86.6 28.6 34.2 - NG 6 10.1 recovered
65 Shyamala 40 f 121/106884 22.8.17
fever,vomiting,hea
dache,
myalgia,pain abd
febrile,dehydrated,
BP-90/60mmHg,epigastric
tenderness+
11.8 10800 72%22%0%1%0% 14 322,000 83.3 28.7 34.2 - NG 6 9.6 recovered
66 Jeyanthi 37 f 225/115931 23.8.17
fever,myalgia,head
ache,
malena
febrile,BP-100/60mmHg,
dehydrated,pallor+
9.6 10100 78%26%0%1%0% 18 96,000 73.2 24.6 32.4
IgM dengue- 
positive
NG 12 74 recovered
67 Kavitha 23 f 122/115853 25.8.17
fever,chills,myalgia
,
arthralgia,pain abd.
febrile,dehydrated,
swelling around ankle jt.
12.8 13900 80%32%1%0%1% 20 268,000 86.8 27.4 34.2
IgM 
chikungunya-
positive
NG 12 86 recovered
68 Surya 28 f 224/115934 26.8.17
fever,myalgia,vomi
ting,
pain abdomen
febrile,dehydrated,
BP-80/60mmHg,pallor+
P/A-epigastric tenderness+
9.2 12800 78%26%0%1%1% 17 170,000 79.8 24.2 32.1
UGIscopy-
erosive gastritis
NG 12 92 recovered
69* Vishwamithran 58 m 213/116767 27.8.17
fever,severe pain 
abdomen,swelling 
in 
abdomen with 
pain,
vomiting,mild 
dyspnoea
febrile,PR-120/mt,pallor+
BP-80/60mmHg, spo2-90%,
hernia-irreducible,abd.-
tender,guarding,rigidity+
BS-sluggish,dehydrated,
dyspnoea+
8.6 22600 92%42%0%1%1% 24 120,000 102.2 42.6 33.1 -
E.coli(ESBL
)
384 1196 expired
HT-3yrs on 
treatment
chronic 
alcoholic
COPD-4yrs on 
treatment,toba
cco 
chewer-5yrs
seizure disorder 
on
irregular 
treatment
seizure disorder 
on
treatment
nil
megaloblastic 
anaemia,umblic
al 
hernia
nil
nil
DM- 8yrs on 
treatment
BA-6yrs on 
treatment
nil
nil
nil
nil
nil
70 Maruthu 40 m 113/131200 28.8.17
fever,vomiting,alte
red
sensorium
febrile,drowsy,dehydrated
BP-90/70mmHg
11.6 12500 79%26%0%1%1% 19 280,000 80.2 27.9 34.8 Hyponatremia NG 6 4.8 recovered
71 Sonu Thakul 25 m 225/116633 30.8.17
fever,chills & 
rigors,
myalgia,headache
febrile,dehydrated,
BP-100/60mmHg,PR-102/mt 11.2 11700 76%32%1%0%0% 16 121,000 79.3 26.1 32.2 PS-P.vivax NG 6 5.6 recovered
72 Sudha 28 f 121/106989 31.8.17
fever,myalgia,pain 
abd,
vomiting
febrile,dehydrated,
BP-80/60mmHg,PR-104/mt
12.4 13900 78%29%0%1%0% 18 245,000 82.2 28.7 33.3
USG abd-
subacute
appendicitis
NG 12 24 recovered
73 Sathya 30 f 224/108118 2.9.17
fever,pain 
abd,vomiting,
myalgia
febrile,icteric,dehydrated,
BP-90/70mmHg,
P/A-epigastric tenderness+
11.5 12800 76%28%0%1%0% 16 189,000 77.4 25.6 31.6
 lepto-
positive2+
NG 12 50 recovered
74 Manibharathi 22 m 145/108387 3.9.17
fever,myalgia,coug
h,
dyspnoea
febrile,dyspnoeic,RR-24/mt
spo2-92%,BP-100/60mmHg,
dehydrated,PR-108/mt.
12.8 13200 70%30%0%1%1% 22 287,000 83.2 27.8 33.7 - NG 6 4.6 recovered
75 Nagaraj 38 m 134/122875 5.9.17
fever,myalgia,redu
ced
oral intake
febrile,dehydrated,
BP-90/70mmHg,PR-102/mt
13.2 12600 76%24%0%1%0% 14 182,000 84.7 26 34.7 - NG 12 3.13 recovered
76 Milanbanuri 30 m 113/122897 7.9.17
fever,pain 
abd,vomiting,
myalgia
febrile,dehydrated,
PR-110/mt,BP-80/60mmHg,
abd-tenderness R 
hypochondrium+guarding+
12.4 16300 78%28%0%0%0% 22 216,000 86.7 28.2 34.1
USG abd- GB 
wall 
thickening
s/o cholecystitis
NG 96 86 recovered
77 Asha 22 f 121/122828 8.9.17
fever,myalgia,head
ache,
bleeding gums
febrile,dehydrated,
BP-90/60mmHg,PR-106/mt
11.6 13600 78%32%0%1%0% 19 89,000 78.7 25.4 32.6
IgM dengue-
positive
NG 12 72 recovered
78 Subbammal 60 f 241/122844 10.9.17
fever,dyspnoea,1 
episode
fits,involuntary 
micturition during 
fits
febrile,drowsy,BP-100/70
mmHg, PR-104/mt,spo2-89%
tongue bite+
11.8 12100 74%22%0%0%1% 18 240,000 80.8 26.4 32.8 - NG 6 3 recovered
79
Sathish
24 m 134/121978 11.9.17
fever, with 
chills,myalgia,
burning 
micturition,
pain abdomen
febrile,BP-100/60mmHg,
PR-102/mt,dehydrated,
P/A-suprapubic tenderness+
13.2 13800 78%36%0%1%0% 18 286,000 85.6 27.9 33.8
urine RE-pus 
cells10-15
urine c/s-
growth+
NG 12 6.8 recovered
80 Dhanalakshmi 60 f 124/127215 13.9.17
fever,cough,dyspn
oea,
myalgia 
febrile,dyspnoeic,spo2-90%
PR-110/mt,BP-110/70mmHg,
RR-24/mt,RS-b/l rhonchi+
12.9 11900 76%32%0%1%0% 22 143,000 88.9 27.2 33.6 - NG 6 7.3 recovered
81 Punitha 53 f 225/130396 14.9.17
fever,chills,myalgia
,
arthralgia,headach
e
febrile,dehydrated,
BP-100/70mmHg, swelling 
around ankle jt
12.8 13600 80%27%1%1%0% 16 280,000 87.8 27.6 34.9
IgM 
chikungunya-
positive
NG 12 84 recovered
82 Raja 52 m 234/145602 16.9.17
fever,pain 
abd,vomiting
febrile,BP-80/60mmHg,
dehydration+,abd- epigastric
tenderness,guarding ,
rigidity+
16.2 17800 82%43%0%0%0% 26 298,000 90.6 32.1 34.6
USG abd-s/o 
pancreatitis
NG 48 74 recovered
83 Suresh 43 m 113/131450 18.9.17
fever,myalgia, 
vomiting,
headache
febrile,dehydrated,
BP-100/70mmHg,PR-104/mt
13.2 13200 74%32%1%0%0% 18 197,000 82.4 27.8 30.1 - NG 6 3.13 recovered
84 Ranjith 41 m 224/141560 20.9.17
fever,myalgia,vomi
ting,
reduced oral intake
febrile,dehydrated,
BP-90/70mmHg,PR-102/mt,
abd- epigastric tenderness+
12.6 14600 80%35%0%1%0% 21 120,000 89.6 33.2 35.2
scrub typhus 
Igm-positive
NG 12 48 recovered
85 Naveen 48 m 225/143682 22.9.17
fever,myalgia,male
na,
headache
febrile,BP-90/60mmHg,eye
congestion,dehydrated
13.9 12800 78%28%0%1%0% 18 90,000 82.6 28.4 32.4
IgM dengue-
positive
NG 24 92 recovered
86 Amudha 42 f 224/139021 23.9.17
fever,myalgia,coug
h,
dyspnoea
febrile,PR-110/mt,spo2-90%
RS-b/l rhonchi,RR-26/min
12.2 13800 76%22%0%1%0% 26 2,67,000 88.2 28.7 33.9 - NG 6 9.4 recovered
seizure disorder-
10yrs
on irregular 
treatment
nil
COPD-9yrs on 
treatment
nil
nil
HT-6yrs on 
treatment
nil
nil
nil
chronic 
alcoholic
BA 6 yrs on 
treatment
nil
nil
BA-3yrs on 
treatment
nil
nil
nil
87 Rajendra prasad 52 m 113/145778 26.9.17
fever, 
vomiting,pain abd,
myalgia, 
hemetemesis
febrile, dehydrated,
PR-106/mt,BP-160/90mmHg
epigastric tenderness-abd
10.4 12900 78%29%0%1%1% 24 1,65,000 76.4 24.3 30.4
UGIscopy-
erosive gastritis
NG 12 96 recovered
88 Murali 35 m 134/146223 27.9.17
fever,malaise,vomi
ting,
pain abd
febrile,hypotension,
dehydrated,icteric,
P/A-mild hepatomegaly
13.6 13600 79%26%0%1%0% 18 2,63,000 82.4 27.3 33.1
 lepto-
positive3+
USG abd-mild 
hepatomegaly
NG 24 88 recovered
89 Geetha 62 f 223/149800 28.9.17
fever,vomiting,pain 
abd,
myalgia
febrile,obese,dehydrated,
PR-106/mt, BP-140/90mmHg
12.8 15600 82%32%0%1%1% 23 2,98,000 80.6 26.4 32.2
USG abd -s/o 
acute
cholecystitis
NG 48 58 recovered
90 Kannan 28 m 145/148600 29.9.17
fever,headache,art
hralgia,
myalgia
febrile,dehydrated,
BP-90/70mmHg,PR-104/mt,
swelling b/l ankle jt.
14.2 14900 77%28%0%1%0% 19 3,67,000 89.8 30.8 34.2
IgM 
chikungunya-
positive
NG 12 82 recovered
91 Komala 35 f 212/149830 30.9.17
fever, myalgia, 
dysuria, 
pain abd, 
headache, inc.
freq. of micturition
febrile, PR-112/mt,
dehydrated,dyspnoeic,
spo2-89%,irritable,RS-L basal
 crepts+,BP-100/70mmHg
abd-suprapubic tenderness+
12.9 16800 82%32%0%1%1% 25 2,60,000 83.6 28.8 32.6
urine acetone-
positive
urineRE-albumin 
2+
pus cells-12-15,
urine c/s-
growth+
NG 48 76 recovered
92* Anbu 55 m 134/150271 2.10.17
fever,pain 
abd,vomiting,
abd.distension,mya
lgia,
reduced urine 
output,
dyspnoea
febrile,BP-110/mt,
dehydrated,BP-106/76mmHg
spo2-88%,abd-tense ascitis
icteric,b/l PE,irritable
10.8 22900 88%42%1%0%1% 28 1,56,000 74.6 24.3 29.8
USG abd-ascitis,
hepatomegaly
E.coli(ESBL
)
384 1158 expired
93 Nalini 42 f 121/153890 3.10.17
fever,headache,my
algia,
vomiting,pain 
abdomen
febrile,dehydrated,
BP-90/70mmHg,
P/A-epigastric tenderness+
13.2 13700 78%26%0%1%0% 18 2,30,000 85.4 28.6 34.9 - NG 6 3.13 recovered
94 Govindan 52 m 113/158901 5.10.17
fever,chills,myalgia
,
headache
febrile,dehydrated,
PR-104/mt,BP-100/70mmHg
11.8 12800 72%24%0%1%0% 16 2,98,000 80.6 26.1 32.8 PS-P.vivax NG 6 3 recovered
95 Anandan 46 m 225/153489 6.10.17
fever,cough,dyspn
oea,
headache,vomiting
febrile, PR-108/mt,
dehydrated,dyspnoeic,
RR-24/mt,spo2-92%,
RS-scattered rhonchi+
13.6 12600 76%27%0%1%1% 18 1,85,000 84.3 34.6 34.2 - NG 12 3.13 recovered
96 Vijayalakshmi 49 f 225/159806 8.10.17
fever,headache,my
algia,
conjunctival 
congestion,
vomiting
febrile,BP-90/60mmHg,
PR-106/mt,conjunctival 
congestion both eyes+,
dehydrated
12.8 13800 78%30%0%2%1% 22 98,000 86.4 27.8 32
IgM dengue-
positive
NG 12 92 recovered
97 muniyan 39 m 223/168961 11.10.17
fever,pain abd, 
vomiting,
myalgia
febrile,PR-108/mt,
BP-100/70mmHg,
epigastric tenderness-abd,
guarding+,dehydrated
16.4 15900 80%35%0%1%0% 24 1,63,000 90.2 34.6 34.1
USG abd-s/o 
Subacute
 pancreatitis
NG 24 32 recovered
98 Aruna 42 f 121/167654 12.10.17
fever,cough with 
expectoration,dysp
noea
febrile,dyspnoeic,
PR-106/mt,spo2-90%,
BP-106/76mmHg,
dehydrated
12.6 14800 82%42%0%1%1% 20 2,64,000 88.2 27.3 33.4
CXRay-infiltrates 
L lung
sputum c/s-
growth+
NG 24 56 recovered
99 Kandan 52 m 224/168650 13.10.17
fever,headache,my
algia,
vomiting
febrile,BP-100/60mmHg,
dehydrated
11.5 13100 78%25%0%1%0% 18 95,000 79.5 24.3 31.6
IgM dengue-
positive
NG 12 96 recovered
100 Krishnaveni 42 f 123/169321 15.10.17
fever,dysuria,pain 
abd,
myalgia
febrile,BP-100/70mmHg,
abd-suprapubic tenderness,
PR-102/mt
12.1 14800 79%28%0%1%0% 16 2,77,000 80.9 26 32.4
urineRE-pus 
cells 10-15
urine c/s-
growth+
NG 24 14.6 recovered
nil
nil
DM-4yrs on 
treatment
nil
DM-12yrs on 
treatment
alcoholic,HT-
4yrs on 
irregular 
treatment
DM 8yrs on 
treatment
nil
nil
chronic 
alcoholic,
HT-7yrs on 
treatment
alcoholic, 
smoker
nil
nil
nil
101 Karuppan 52 m 113/166932 16.10.17
fever,vomiting,mya
lgia,
reduced oral intake
febrile,icteric,PR-108/mt,
abd-hepatomegaly,
dehydrated
11 13900 75%26%0%1%0% 22 1,46,000 78.3 25.4 31.1
elevated liver 
enzymes
USG abd-
hepatomegaly,
s/o hepatitis
NG 48 78 recovered
102 Ramasamy 44 m 145/166946 2.11.17
fever,myalgia,head
ache,
arthralgia
febrile, dehydrated,
BP-90/60mmHg,b/l ankle 
swelling+warmth+
tenderness+
13.6 13200 74%27%0%1%0% 17 2,24,000 88.6 28.5 33.8
IgM 
chikungunya-
positive
NG 12 82 recovered
103 Hari 48 m 134/167352 8.11.17
fever,headache,co
ugh,fits
1 episode
febrile,postictal phase,
PR-110/mt,BP-106/66mmHg,
tongue bite+
14.3 12800 72%22%0%0%0% 19 1,98,000 92.1 34.2 35.4 - NG 6 3.4 recovered
104 Ramya 32 f 123/167785 10.11.17
fever,myalgia,vomi
ting,
pain abd
febrile,dehydrated,
BP-100/70mmHg
13.4 13600 70%25%0%1%1% 18 1,20,000 84.2 27.6 32.4
IgM scrub 
typhus-
positive
NG 12 96 recovered
105 Ramesh 45 m 225/168501 12.11.17
fever,vomiting,pain 
abdomen,giddiness
febrile,PR-106/mt,BP-90/70
mmHg,dehydrated,P/A-
guarding+,rigidity+,
tenderness R iliac region+
11.8 16100 82%40%0%1%0% 22 2,10,000 86.2 29.4 34.1
USG abdomen-
F/S/O
acute 
appendicitis
NG 48 72 recovered
106 Keerthana 46 f 121/169002 15.11.17
fever,reduced oral 
intake,
vomiting,myalgia,p
ain abd
febrile,icteric,BP-100/70
mmHg,PR-102/mt,P/A-
hepatomegaly+
10.9 12100 74%29%0%1%0% 18 1,98,000 89.4 28.6 33.2
 Lepto-
positive3+
USG abd-
Hepatomegaly
NG 24 98 recovered
107 Radhika 42 f 123/170910 17.11.17
fever with 
rigors,myalgia,
headache,reduced 
oral 
intake,vomiting-1 
episode
febrile,dehydrated,BP-96/70
mmHg,PR-106/mt,P/A-
splenomegaly
10.3 14500 78%28%0%1%0% 17 2,40,000 78.2 24.9 32.1
P.S-P.vivax
USG abd-
splenomegaly
NG 12 3.1 recovered
108 Ravi 30 m 111/171231 20.11.17
fever,vomiting,pain 
abd,
weakness both 
lower limbs
febrile,dehydrated,BP-100/70
mmHg,PR-102/mt,P/A-soft
epigastric tenderness+
B/L lower limb-tone,power
reduced,plantar reflex-normal
11.6 12300 74%26%0%0%1% 19 2,26,000 82.8 26.4 33.5 Hypokalemia NG 6 3.6 recovered
109 Aruna 45 f 122/173456 25.11.18
fever with 
chills,myalgia,
pain lower 
abdomen
febrile,PR-106/mt,BP-100/70
mmHg,P/A-suprapubic
tenderness+
12.6 13800 78%28%0%1%0% 18 1,96,000 84.6 27.2 32.8
urine RE-10-
15pus cells+
urine C/S-
growth+
NG 12 9.8 recovered
110 Azhagu 35 f 121/173960 26.11.18
fever,cough with 
expectoration,dysp
noea,
reduced oral intake
febrile,PR-112/mt,BP-100/70
mmHg,RS-B/L rhonchi,L basal
crepts+dehydrated
11.4 14200 80%28%0%1%0% 22 2,16,000 78.9 24.2 31.4
CXR-F/s/o 
chronic 
bronchitis
NG 12 74 recovered
111 Poongodi 43 f 123/176904 26.11.18
fever,altered 
sensorium,
dyspnoea,vomiting-
recurrent,reduced 
oral
intake,bladder 
incontinence
febrile,PR-120/mt,BP-90/60
mmHg,dehydrated,spo2-89%
drowsy,disoriented,dyspnoeic
CVS/RS-NAD,P/A-soft,power
tone both upper and lower
limbs -normal,plantar reflex-
normal.
12.6 13100 74%26%0%0%0% 14 2,26,000 82.4 27.6 34.2
High blood 
sugar levels
ABG analysis 
showed
f/o acidosis
urine acetone-
positive
Hyponatremia
NG 24 106 recovered
112* Rathnam 69 m 212/178120 27.11.18
fever,dyspnoea,cou
gh,
reduced urine 
output
swelling both legs
febrile,BP-90/60mmHg,PR-
110/mt,RS-L basal crepts,
b/l pedal edema+,RR-28/mt
10.2 23800 82%38%0%1%0% 24 1,90,000 78.6 24.2 30.4
CXR-infiltrate L 
lung,f/s/o
consolidation
Staphyloc
occus 
aureus
192 472 recovered
HT-5yrs on 
treatment
seizure disorder-
skipped regular 
medicines-15 
days
DM-10yrs on 
irregular
treatment
BA on 
treatment -7yrs
alcoholic,smoke
r
alcoholic
nil
nil
nil
Hypothyroid on 
treatment since 
4yrs
DM-12yrs on 
treatment
smoker,alcoholi
c
DM-3yrs on 
treatment
113 Govindraj 45 m 113/178291 27.11.18
fever,vomiting,hea
dache,
myalgia,pain abd
febrile,PR-102/mt,BP-80/60
mmHg,RS-b/l basal crepts
12.6 13400 80%22%0%1%0% 18 92,000 79.4 26.8 32.1
CXR-b/l lung 
infitrates
IgM dengue-
positive
NG 24 72 recovered
114 Arul 32 m 113/179231 28.11.18
fever,myalgia,arthr
algia,
vomiting
febrile,BP-100/60mmHg,PR-
104/mt,CVS/RS-NAD,P/A-
soft.
11.4 14200 81%24%0%1%0% 16 1,56,000 88.6 27.4 31.4
IgM 
Chikungunya-
positive
NG 12 84 recovered
115 kannan 62 m 124/179432 29.11.18
fever,altered 
sensorium,
vomiting,fits-1 
episode,
urinary 
incontinence+,
dyspnoea
febrile,BP-100/70mmHg,PR-
102/mt,drowsy,spo2-88%
RS-added sounds,CVS-NAD,
P/A-soft
12.2 13800 78%26%0%0%0% 20 1,98,000 82.6 26.4 32.6
hyponatremia,C
T brain-
L -GC 
hypodensity
NG 6 4.6 recovered
116 Nallathambi 42 m 123/179542 30.11.18
fever,dysuria,pain 
abdomen,myalgia,
fever associated 
with
chills and rigors
DM-10yrs 
on irregular
treatment
febrile,BP-90/60mmHg,PR-
106/mt,P/A-suprapubic 
tenderness+,dehydrated
12.4 15200 84%28%0%1%0% 18 2,60,000 84.2 27.4 34.2
urine RE-10-
15pus cells+
urine C/S-
growth+
NG 12 3.4 recovered
117 Gokul 35 m 113/179641 30.11.18
fever with chills 
and rigors,
myalgia, vomiting
febrile,BP-100/70mmHg,
PR-102/mt,CVS/RS-NAD,
P/A-splenomegaly+,CNS-NAD
11.8 13100 82%27%1%0%0% 18 1,50,000 82.2 26.8 32.2
PS-P.vivax
USG abd-mild 
splenomegaly
NG 12 4.2 recovered
118 Kaviyarasan 28 m 125/179952 5.12.18
fever,cough,dyspn
oea,
reduced oral intake
febrile,dyspnoeic,spo2-91%,
PR-110/mt,RS-L basal crepts,
scattered rhonchi+
12.2 12500 86%29%0%1%0% 20 2,10,000 85.8 28.4 34.6
CXR-bronchitis 
with
consolidation L 
lung
NG 12 60 recovered
119 Durga 29 f 121/181204 10.12.18
fever,pain 
abdomen,
vomiting,giddiness
febrile,BP--90/60mmHg,
PR-102/mt,dehydrated,
P/A-tenderness R 
hypochondrium+
guarding+BS+
11.4 13200 82%28%1%0%0% 16 1,90,000 82.4 27.6 33.2
USG abd-s/o 
acute 
cholecystitis
NG 48 82 recovered
120 Balu 56 m 113/183621 15.12.18
fever,dyspnoea,cou
gh
reduced urine 
output,
fever associated 
with chills
chest pain
febrile,dehydrated,
dyspnoeic,spo2-90%,RR-28/mt,
RS-L basal crepts +
12.6 14800 86%29%0%1%0% 20 1,80,000 88.2 25.6 32.4
CXR-L lung 
minimal 
pleural 
effusion+
sputum c/s-
growth+
NG 24 74 recovered
         
**121
Chandran 45 m 123/184562 19.12.18
fever,with chills, 
vomiting,
myalgia,pain 
abdomen,
dyspnoea
febrile,dehydrated,dyspnoeic
PR-108/mt,BP-90/60mmHg
RS-L basal crepts,spo2-89%,
RR-36/mt
11.2 15600 88%30%0%1%0% 22 69,000 78.2 23.6 31.4
CXR-L lung 
minimal 
pleural 
effusion+,
USG abd-GB 
wall edema+
minimal ascitis+
IgM dengue- 
positive
NG 96 110.2 expired
122 Kavitha 28 f 121/186234 26.12.18
fever,cough,dyspn
oea,
vomiting,reduced 
oral 
intake,myalgia
febrile,dyspnoeic,PR-100/mt,
BP-100/60mmHg,RR-28/mt,
RS-b/l rhonchi+,L basal crepts
12.6 18200 87%28%0%1%1% 24 1,89,000 84.6 28.4 33.2
CXR-b/l lung 
infitrates+
sputum c/s-
growth+
NG 12 46 recovered
123 Anand 42 m 125/187635 28.12.18
fever,myalgia,reuc
ed oral
intake,vomiting+
febrile,BP-90/60mmHg,PR-
98/mt,CVS/RS-NAD,P/A-
epigastric tenderness+
mild splenomegaly
11.6 13600 82%26%1%0%0% 18 1,20,000 82.4 26.6 32.4
IgM scrub 
typhus-
positive
NG 12 98 recoverednil
alcoholic-10yrs,
seizure disorder-
6yrs
on irregular 
treatment
nil
nil
smoker
BA since 6yrs
nil
smoker-10yrs,
nil
nil
nil
124 Devi 42 f 121/188652 2.1.18
fever,with 
chills,pain lower
abdomen,myalgia
febrile,dehydrated,PR-102/mt
BP-100/70mmHg,P/A-soft,
suprapubic tenderness+
10.8 12800 81%24%0%1%0% 16 1,96,000 76.8 26.2 31.8
urine RE-pus 
cells 10-15
urine c/s-
growth+
NG 24 4.2 recovered
125 Arul 42 m 124/189652 6.1.18
fever,altered 
sensorium,
urinary 
incontinence,
fits-1 
episode,vomiting
febrile,dyspnoeic,PR-110/mt
BP-160/100mmHg,RR-38/mt
spo2-88%,RS-added sounds
tongue bite+
11.8 14600 82%26%0%1%0% 20 1,72,000 86.6 27.6 32.8
CT brain-
heterodense
lesion in R 
temporoparietal
region with 
specks of 
calcification 
seen
NG 6 3.6 recovered
126 Vigneswaran 32 m 223/189832 10.1.18
fever,scrotal 
swelling L,
pain,myalgia
febrile,L scrotal edema+
L inguinal lymphadenopathy
dehydrated,BP-100/70mmHg
12.6 15400 88%28%1%1%0% 18 2,20,000 82.4 28.2 32.2
I &D done and 
pus c/s-
growth+
NG 24 72 recovered
127 Mohan 36 m 234/192983 12.1.18
fever,hematuria,pa
in
abdomen,vomiting,
reduced urine 
output
febrile,dehydrated,BP-100/70
mmHg, PR-102/mt,P/A-
diffuse tenderness+no
guarding/rigidity
13.2 16400 86%24%0%0%0% 14 1,86,000 84.6 31.2 34.2
urine RE-pus 
cells+RBC+
albumin+++
USG abd-s/o 
acute
glomerulonephri
tis
NG 24 120.6 recovered
128 Gandhi 32 m 256/194328 14.1.18
fever,severe pain 
abdomen
vomiting,reduced 
oral 
intake,myalgia
febrile,PR-106/mt,BP-80/60
mmHg,P/A-tenderness R iliac
region, guarding+rigidity+
12.6 13600 88%28%0%0%0% 12 2,60,000 82.2 26.8 32.6
USG abd-s/o 
acute
appendicitis
NG 96 82 recovered
129 Anitha 42 f 121/195692 15.1.18
fever,arthralgia,my
algia,
vomiting
febrile,dehydrated,
BP-100/70mmHg,PR-102/mt
b/l ankle edema+,swelling
smaller joints of hands
11.8 13800 82%24%0%1%0% 16 1.92,000 84.6 27.2 34.4
IgM 
chikungunya-
positive
NG 12 86 recovered
130 Karunanithi 56 m 235/196783 17.1.18
fever,pain 
abdomen,
vomiting,myalgia,h
/o
passage of high 
coloured
urine,h/o malena
febrile,BP-90/60mmHg,
PR-108/mt,icterus+
pallor+,P/A-hepatomegaly+
tenderness R hypochondrium 
9.6 15800 88%28%0%1%0% 22 1,76,000 76.5 24.6 30.2
USG abd-
hepatomegaly
gallstones+
f/s/o-
obstructive 
jaundice
NG 24 98 recovered
131 Palani 45 m 124/197832 18.1.18
fever,with chills 
and rigors
myalgia,headache
febrile,dehydrated,
BP-100/70mmHg,PR-102/mt
P/A-mild splenomegaly,
11.2 13200 84%26%1%0%0% 12 2,26,000 80.2 26.6 32.2
USG abd-mild 
splenomegaly
PS-P.vivax
NG 12 10.1 recovered
132 Sakthi 28 f 111/198372 20.1.18
fever,pain 
abdomen,
myalgia,vomiting
febrile,dehydrated,icteric,
BP-110/70mmHg,PR-106/mt
P/A-hepatomegaly+
12.6 14100 86%26%0%1%0% 14 1,98,000 82.6 28.6 33.2
USG abd-mild
hepatomegaly
lepto positive 2+
NG 12 72 recovered
133 Arunai 53 f 213/199764 22.1.18
h/o unknown bite L 
foot
swelling at local 
site,pain+
h/o fever+
febrile,BP-90/60mmHg,
PR-108/mt,RR-22/mt,
swelling ,redness at local site
L foot,no obvious bite mark,
drowsy,CVS/RS-NAD,P/A-
soft.
12.4 13200 84%24%0%1%0% 16 1,50,000 84.6 27.6 32.4
I&D done,pus 
c/s-
growth+,BT/CT-
normal
NG 48 78 recovered
134 Latha 32 f 121/199872 24.1.18
fever,dysuria,reduc
ed 
urine output, pain 
abd,
febrile,BP-90/60mmHg,
PR-104/mt,dehydrated,
P/A-diffuse tenderness+
10.9 15600 82%26%0%1%0% 18 2,60,000 78.4 24.6 31.2
elevated renal 
parametes
urine RE-
albumin++,
pus cells-10-15
urinec/s-
growth+
NG 12 60 recovered
DM -7yrs on 
treatment
alcoholic,
DM-5yrs on 
irregular 
treatment
nil
nil
nil
nil
nil
DM-4yrs on 
treatment
nil
DM since 4yrs 
on 
treatment
alcoholic,seizur
e 
disorder on 
irregular
treatment
135* Ravi 62 m 111/218926 26.1.18
fever,altered 
sensorium
dyspnoea,cough,
chest 
pain,sweating,
myalgia
febrile,drowsy,dyspnoeic
spo2-89%,PR-110/mt,
BP-86/60mmHg,CVS-NAD,
RS-L basal crepts+B/L rhonchi
pallor+,dehydrated
9.6 20600 88%32%1%1%0% 22 1,20,000 75.2 25.4 30.6
CXR-f/s/o 
consolidation
L lung with 
moderate 
pleural effusion
Staphyloc
occus 
aureus
192 730 recovered
136 Punitha 54 f 121/238920 27.1.18
fever with 
chills,pain
abdomen,dysuria,
vomiting
febrile,PR-102/mt,BP-80/60
mmHg,dehydration+
P/A-soft,suprapubic 
tenderness+
11.2 13800 80%24%0%1%0% 16 1,90,000 85.6 26.4 32.8
urine RE
albumin-2+
pus cells-10-15
urine C/S-
growth+
NG 12 54 recovered
137 Saranya 35 f 125/238981 30.1.18
fever,severe 
arthralgia,
myalgia,vomiting
febrile, BP-90/60mmHg,
PR-98/mt,swelling B/L ankle,
smaller joints of hands,
CVS/RS-NAD,P/A-soft,
CNS-NAD
10.6 12900 82%22%1%0%0% 20 2,68,000 79.6 24.8 33.6
IgM 
chikungunya-
positive
NG 24 45 recovered
138 Govindan 45 m 111/239726 31.1.18
fever,vomiting,pain 
abdomen,h/o 
passing
high coloured 
urine,
reduced oral 
intake,
myalgia
febrile,icteric,dehydrated,PR-
96/mt,BP-96/60mmHg,
P/A-mild hepatomegaly
12.8 14600 78%29%0%1%0% 18 1,96,000 88.6 28.4 34.6
Leptospirosis-
3+positive
NG 24 76 recovered
139 Kavitha 48 f 235/239982 2.2.18
fever with 
chills,ulcer L foot
3days, severe pain 
L foot 
associated with 
swelling,
h/o trauma L foot 
febrile,BP-80/60mmHg,
PR-102/mt,ulcer L foot
with serosanguinous 
discharge,L inguinal
lymphadenopathy
11.6 15600 82%32%0%1%0% 24 2,16,000 80.6 26.8 32.6 pus c/s-growth+ NG 12 52 recovered
140* Periyasamy 56 m 206/242019 3.2.18
fever,dyspnoea,che
st 
discomfort,vomitin
g,
sweating,restlessne
ss,
reduced oral intake
febrile,restless,dyspnoeic,
spo2-88%,PR-108/mt,
BP-190/100mmHg,RS-b/l 
basal crepts,CVS-NAD,
P/A-hepatomegaly
12.6 21900 89%36%0%1%1% 26 1,98,000 82.6 28.6 31.8
CXR-b/l lung 
infiltrates
USG abd-
hepatomegaly
Elevated liver 
enzymes.
Staphyloc
occus 
aureus
192 800 recovered
141 Karuppusamy 62 m 145/243217 5.2.18
fever,cough with 
expectoration,
hemoptysis,chest 
pain,
dyspnoea
febrile,BP-100/70mmHg,
PR-106/mt,dyspnoeic,spo2-
89%,RS-b/l extensive rhonchi
pallor+
9.8 14800 86%34%0%1%1% 26 2,56,000 74.6 24.5 29.6
CXR-f/s/o 
chronic 
bronchitis
NG 12 48 recovered
142 Sekar 35 m 224/24467 6.2.18
fever,severe pain 
abdomen,
vomiting,headache
,
myalgia
febrile, BP-80/60mmHg,
PR-104/mt,P/A-tenderness
R iliac fossa,guarding,
rigidity+dehydration+
10.6 18200 88%36%0%1%0% 24 1,88,000 79.4 25.6 30.6
USG abd-s/o 
acute 
appendicitis.
NG 24 96 recovered
143 Kamala 46 m 232/24486 7.2.18
fever,vomiting,mya
lgia,
pain 
abdomen,reduced
oral intake
febrile,BP-90/60mmHg,
PR-98/mt,dehydrated,obese
P/A-tenderness R 
hypochondrium+
11.8 15800 86%32%0%0%1% 18 2,26,000 84.6 28.2 33.8
USG abd-s/o 
acute
cholecystitis
NG 24 32 recovered
nil
DM since 8yrs 
on 
irregular 
treatment
chronic smoker
smoker, 
alcoholic
DM since 10yrs 
on 
irregular 
treatment 
nil
DM since 6yrs 
on 
treatment
nil
HT-since 10yrs 
on 
treatment,DM-
since
5yrs on 
irregular 
treatment
DM since 5 yrs 
on 
treatment
144* Abdul basha 56 m 125/24578 8.2.18
fever,dyspnoea,cou
gh,
reduced urine 
output
swelling both 
legs,reduced 
oral intake,
febrile,dyspnoeic,spo2-88%,
b/l pedal edema+pallor+
BP-150/100MMHg,PR-106/
mt,RR-28/mt,CVS-NAD
RS-L basal crepts,
P/A-hepatomegaly
10.4 23600 89%28%0%1%0% 24 1,88,000 78.6 25.4 30.6
CXR-L pleural 
effusion
USG abd-
hepatomegaly
Acinetoba
cter spp.
192 782 recovered
145 Veerasamy 48 m 236/24589 9.2.18
fever,vomiting,
hemetemesis,pain 
abdomen
reduced oral intake
febrile,dehydrated,pallor+
icteric,P/A-hepatomegaly,
tenderness epigastric region+
9.4 14900 84%32%1%0%0% 22 2,65,000 76.8 24.4 31.6
USG abd-
hepatomegaly
UGIscopy-
erosive 
gastritis
NG 12 54 recovered
146 Gurusamy 52 m 145/24687 11.2.18
fever,altered 
sensorium,
fits 1 episode 
,vomiting,
involuntary 
micturition
febrile,drowsy,BP-140/100
mmHg,PR-108/mt,spo2-89%
RS-added sounds,
tongue bite+
11.2 12600 82%31%0%0%1% 18 2,42,000 78.2 26.4 32.6
hyponatremia,
CT brain-
hypodense 
lesion in L 
parieto
temporal region
NG 6 11 recovered
147 Paneer 48 m 212/24738 13.2.18
fever,dyspnoea,my
algia,
bleeding 
gums,cough
febrile,BP-80/60mmHg,
PR-108/mt,pallor+dyspnoeic
spo02-88%,drowsy,RS-b/l
basal crepts
10.2 15700 86%34%0%1%0% 26 90,000 77.4 26.8 31.8
CXR-b/l lung 
infitrates
IgM dengue-
positive
NG 24 42 recovered
148 Gopal 44 m 124/24892 17.2.18
fever with chills 
and rigors
myalgia,vomiting
febrile,BP-90/60mmHg,
PR-106/mt,P/A-splenomegaly
dehydrated
12.8 13800 82%28%0%1%0% 18 2,64,000 82.8 27.2 33.4 PS-P.vivax + NG 6 36 recovered
**149 Mani 35 m 212/24902 21.2.18
fever,vomiting,hea
dache,
myalgia,pain 
abdomen,
cough,dyspnoea
febrile,dehydrated,
dyspnoeic,spo2-90%,
BP-80/60mmHg,PR-98/mt,
P/A-hepatomegaly,
RS-L basal crepts, 
12.4 12100 80%32%0%1%0% 22 86,000 84.8 29.4 34.6
USG abd-
hepatomegaly
CXR-minimal L 
pleural 
effusion,
IgM dengue-
positive
NG 96 120.6 expired
150 Saravanan 56 m 235/25679 27.2.18
fever,vomiting,pain 
abdomen,vomiting,
hemetemesis,redu
ced oral
intake
febrile,dehydrated,BP-90/60
mmHg,PR-102/mt,icteric,
P/A-hepatomegaly,
tenderness epigastric region+
11.6 14800 86%34%0%1%0% 24 1,98,000 84.8 27.6 32.4
USG abd-
hepatomegaly
UGI scopy-
erosive
gastritis
NG 12 58 recovered
nil
nil
chronic 
alcoholic
nil
chronic 
alcoholic,
chronic smoker,
seizure disorder 
on 
irregular 
treatment
chronic 
alcoholic
DM-since 12 yrs 
on 
irregular 
treatment,
chronic smoker,
alcoholic
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Outcome
CRP 
(mg/l)
IL-6 (pg/ml)
PCR(gene 
detected)
*17 turbid
Mac-LF opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
cip-
R
Pen-
s
cot-
s
LZ-
s
Tet-
s
CX-
s
Ery-
s
-
VAN
s
recovered 192 425 -
*20
turbid,
lysis+
Mac-NLF colonies GNB positive - positive motile - K/NC positive -
Pseudomonas
aeruginosa
Ak-
s
Pt-
s
Gm-
s
cip-
s
Imp-
s
CAZ-
R
- - expired 384 1180 -
*25 turbid
Mac-LF opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
cip-
s
Pen-
s
Ery-
s
LZ-
s
Tet-
s
CX-
s
cot-
R
-
VAN
s
recovered 192 568 -
*27 turbid
Mac-LF opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
cip-
R
Pen-
s
LZ-
s
CX-
s
Tet-
s
Ery-
s
cot-
R
-
VAN
s
recovered 192 482 -
*29 turbid
Mac-LF opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
Pen-
s
Ery-
s
LZ-
s
Tet-
R
CX-
s
cip-
R
cot-
R
-
VAN
s
recovered 192 620 -
*45 turbid Mac-LF colonies GNB positive - - motile Positive A/A - - E.coli(ESBL)
Ak-
s
ctx-
R
Gm-
R
cip-
R
cot-
R
Amp-
R
Tet-
s
- recovered 384 856
CTX-M,
TEM 
*69 turbid Mac-LF colonies GNB positive - - motile Positive A/A - - E.coli(ESBL)
Ak-
s
Gm-
s
Ctx-
R
cip-
R
cot-
R
Tet-
s
Amp-
R
- expired 384 1196
CTX-M,
TEM 
*92
turbid,
lysis+
Mac-LF colonies GNB positive - - motile Positive A/A - - E.coli(ESBL)
Ak-
s
Gm-
R
Ctx-
R
cip-
R
cot-
R
Amp-
R
Tet-
s
- expired 384 1158
CTX-M,
TEM 
*112 turbid
Mac-LF opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
cip-
s
Ery-
s
Pen-
S
LZ-
s
tet-
s
cot-
R
CX-
s
-
VAN
s
recovered 192 472 -
*135 turbid
Mac-LF Opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MSSA)
Ery-
s
Pen-
s
cot-
s
cip-
R
LZ-
s
Tet-
s
CX-
s
-
VAN
s
recovered 384 730 -
*140 turbid
Mac-LF Opaque
colonies
GPCclusters positive
slide/tube
positive
- - - A/A - -
Staphylococcus
aureus(MRSA)
LZ-
s
cip-
s
Ery-
s
cot-
R
Tet-
R
Pen-
R
CX-
R
-
VAN
s
recovered 192 800 mecA
*144
turbid,
lysis+
Mac-NLF colonies GNB positive - -
non-
motile
- K/NC Positive -
Acinetobacter
spp.
Pt-
s
Tet-
s
Ak-
R
Gm-
R
cip-
R
CAZ-
R
Imp-
s
cot-
R
recovered 384 782 -
A
nt
ib
io
gr
am
 * CULTURE POSITIVE CASES
